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Abstract
Christa M. Donegan
BEHAVIORAL EFFECTS OF NOVEL TREATMENTS FOR PAIN AND
ALCOHOL USE DISORDER
2020-2021
Thomas M. Keck, Ph.D.
Master of Science in Pharmaceutical Sciences

Opioid use disorder (OUD) and alcohol use disorder (AUD) are pressing public
health problems in the United States that require new pharmacotherapies to be explored.
Current FDA-approved treatment options for these two disorders are only moderately
effective. Thus, there is a demand for the identification of new targets for drug
development. Previous research initiatives have shown that when morphine is coadministered with the novel imidazodiazepine, MP-III-024, synergistic effects in models
of analgesia and antinociception are produced. Our research efforts were concerned with
understanding if morphine in combination with MP-III-024 produced synergistic effects in
measures of undesirable pharmacological responses: opioid side effects. The results of our
operant self-administration tests demonstrated that MP-III-024 does not enhance morphine
induced disruptions; and in models of locomotor function, our 1.0:0.94 morphine:MP-III024 ratio demonstrated a statistically significant subadditive (anti-synergistic) effect. With
these findings, we now know that morphine and MP-III-024 are not universally synergistic.
Concerning AUD, the dopamine D4 receptor (D4R) full antagonist, CAB-01-019, was
studied through palatable food self-administration testing. Our results showed that CAB01-019 did not significantly reduce behavioral responses at any of the three tested doses
(10, 17.8, and 30 mg/kg). These palatable food self-administration tests with CAB-01-019
will serve as a critical control for future alcohol tests.
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Chapter 1
The Impact of Opioids and Alcohol on Society and the Need for New Treatment
Methods for Substance Use Disorders without Addiction Risks

1.1. Part 1 – Opioids

1.1.1. Definitions
1.1.1.1. Drug Interactions.
▪

Additive effect: occurs when the effects of a drug combination equal the sum of the
expected effects of the two drugs alone (e.g., 1 +1 = 2)[1]

▪

Subadditive (anti-synergistic) effect: occurs when the effects of a drug combination
are less than the expected sum (e.g., 1 + 1 < 2)[2]

▪

Superadditive (synergistic) effect: occurs when the effects of a drug combination
are greater than the expected sum (e.g., 1 + 1 > 2)[1]

▪

Homergic effect: refers to two drugs having the same maximal effect[3]

▪

Heteroergic effect: refers to one drug having an effect and the other drug lacking
the effect[3]

▪

Agonist: a substance that binds to receptors in the brain and produces a
physiological response; some agonists imitate neurotransmitters associated with
pain and pleasure (e.g., nicotine and heroin)[4]

▪

Antagonist: a substance that binds to receptors in the brain and interferes with or
blocks certain chemical reactions (e.g., naloxone and naltrexone)[4]
1

▪

Allosteric modulator: a substance that binds to a receptor at a site distinct from the
active (orthosteric) site; causes a conformational change in the receptor, thus
altering the endogenous ligand’s affinity (probability the ligand will bind to the
receptor) and efficacy (ligand’s ability to activate the receptor)[5,6]
➢ Positive allosteric modulator (PAM): increases affinity and/or efficacy[5]
➢ Negative allosteric modulator (NAM): decreases affinity and/or efficacy[5]

Figure 1
Drug Interactions: Agonists, Antagonists, and Allosteric Modulators

Note. The active (orthosteric) site of a receptor is where agonists or antagonists bind in
order to produce an effect. Contrastingly, the allosteric site of a receptor is where allosteric
modulators bind to exert their effect; agonists and antagonists are unable to bind to the
2

allosteric site. There are two main types of allosteric modulators: positive allosteric
modulators (PAMs) and negative allosteric modulators (NAMs). PAMs help to potentiate
the effect of the receptor and increase the affinity and/or efficacy of agonists or antagonists,
whereas NAMs inhibit the effect of the receptor and decrease the affinity and/or efficacy
of agonists and antagonists.[7]

1.1.1.2. Responses to Pain.
▪

Analgesia: the process of relieving or reducing pain, oftentimes through the use of
pharmacotherapy with an analgesic (e.g., Tylenol® and Advil®)[8]

▪

Hyperalgesia: an increased sensitivity to pain; opposite of antihyperalgesia[9]

▪

Antinociception: the inhibition of nociception, which is the neural processes used
to detect painful or noxious stimuli[10,11]

1.1.2. History of Opioids
There is evidence to suggest that opioid-based analgesics have been used for
thousands of years.[12] In Mesopotamia (what is now present-day Iraq and sections of Iran,
Turkey, Syria, and Kuwait), the opium poppy plant, also known as Papaver somniferum,
was cultivated for its active ingredients as far back as 3000 BCE.[12] More recently,
throughout the 1500s to 1800s, laudanum, an alcoholic solution containing opium and
several other ingredients, was used as a popular painkiller and cough suppressant in
European medicine.[12] Nevertheless, modern opioid pharmacology was not truly born until
the discovery of morphine in 1806 by Friedrich Sertürner, a German pharmacist.[12]
Sertürner was the first scientist to successfully isolate morphine crystals from the opium
3

poppy plant.[13] Along with being the first alkaloid to be extracted from opium, morphine
was also the first alkaloid to be isolated from any plant.[13] Therefore, Sertürner is often
recognized as a pivotal pioneer of alkaloid chemistry.[13] However, it was not until the
invention of the hypodermic needle and syringe by Scottish physician, Alexander Wood,
and French surgeon, Charles Gabriel Pravaz, in 1853, that the administration of morphine
became clinically widespread.[12,14]
In the 1860s, the use of opioids for the purpose of treating pain started to become
prevalent during the United States’ Civil War.[15] When injured, soldiers were administered
morphine as a means of analgesia.[15] In the years following wartime, many men began
developing dependencies and addictions to this drug, thus foreshadowing the emergence
of a public health crisis that would occur years later.[15]
In 1898, heroin was introduced to the public by the German pharmaceutical firm,
the Bayer Company, after investigating a chemical modification to morphine that made it
more palatable as a cough suppressant.[15,16] The Bayer Company named their new, what
they thought to be “wonder” drug, heroin, and advertised it as being less habit-forming
than morphine.[15,16] Not long after hitting the market, physicians and pharmacists began
noticing that many patients taking heroin were becoming very dependent on the drug and
larger doses were required to produce therapeutic effects after repeated administration.[16]
Eventually, due to its highly addictive nature, heroin was removed from commercial sale
and a total ban was placed on its production.[17]
During the 1910s and 1920s, the United States began enforcing stringent
regulations on drugs classified as opioids and narcotics.[15] These types of drugs now
required formal prescriptions to be written by a licensed physician in order for patients to
4

receive them; opioids and narcotics were no longer available over the counter.[15] In the
1970s, further restrictions on opioids and narcotics were passed with the issuance of the
Controlled Substances Act, which divides drugs into different groupings based on their
abuse liability and imposes regulations contingent on the class.[15]
Moreover, in 1995, Purdue Pharma introduced the drug, OxyContin®, a version of
the already available opioid, oxycodone.[15] Scientists at Purdue Pharma claimed
OxyContin® to be a gentler and less addictive analgesic when compared to other opioid
pills.[15] Therefore, over the next couple of decades, doctors would readily prescribe
OxyContin®, along with other opioids as an easy means of treating pain.[15] This over
prescription of exceedingly addictive drugs would eventually fuel what we now know to
be the Opioid Epidemic. As of October 2017, the United States has officially declared a
public health emergency in response to the over prescription and misuse and abuse
surrounding opioids.[15]

1.1.3. Classification of Opioid Drugs
Clinical opioids can be classified into three groups:
▪

Naturally occurring: alkaloids that are directly extracted from the opium poppy plant[18]

▪

Semi-synthetic: opioids produced by scientists in a laboratory from natural opiates; for
example, chemical manipulations to the natural plant alkaloid, morphine, have yielded
semi-synthetic compounds, such as heroin[18]

▪

Synthetic: opioids that are entirely manmade in a laboratory[18]

Opioids can be classified into three groups based on their interaction with opioid receptors:

5

▪

Full agonists: tightly bind to opioid receptors to produce a maximal effect[19]

▪

Partial agonists: activate opioid receptors but to a lesser extent than full agonists[19]

▪

Antagonists: bind to opioid receptors to reverse or block the effects of opioids[20]

Table 1
Classifications of Opioids
Origin

Function

Analgesic Effects

Naturally occurring:
• Morphine
• Codeine
• Thebaine
• Papaverine

Full agonists:
• Morphine
• Codeine
• Heroin
• Oxycodone
• Hydrocodone
• Fentanyl
• Methadone
Partial agonists:
• Buprenorphine
• Tramadol

Strong:
• Morphine
• Fentanyl
• Methadone
• Meperidine

Antagonists:
• Naloxone
• Naltrexone

Weak:
• Codeine

Semi-synthetic:
• Heroin
• Oxycodone
• Hydrocodone
• Buprenorphine
Synthetic:
• Fentanyl
• Methadone
• Tramadol
• Meperidine

Intermediate:
• Buprenorphine

Note. Opioids categorized by their origin, function, and analgesic potency (strength)[12,21]
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1.1.4. Classification of Opioid Receptors
Opioids work by attaching to proteins, called opioid receptors, which are found throughout
the central and peripheral nervous system at various levels of expression in different tissue
types. Many opioid receptors are located on nerve cells in the brain, spinal cord, and gut,
as well as a plethora of other areas of the body associated with regulating pain.[22] There
are currently four known opioid receptors which include:
▪

μ-opioid receptors (MORs): found primarily in the periaqueductal grey region of the
midbrain and the superficial dorsal horn of the spinal cord; responsible for opioid
analgesia, as well as many opioid side effects (e.g., respiratory depression, constipation,
tolerance, dependence, and abuse liability)[21,23]

▪

κ-opioid receptors (KORs): located in the limbic and other diencephalic areas, brain
stem, and spinal cord; help mediate spinal analgesia[21]

▪

δ-opioid receptors (DORs): largely present in the brain; effects are not well known but
also thought to have antinociceptive effects[21]

▪

Nociception/orphanin opioid receptors (NOPs): found predominantly in the brain (i.e.,
cortex, amygdala, bed nucleus of the stria terminalis, medial prefrontal cortex, ventral
tegmental area, lateral hypothalamus, and nucleus accumbens) and many brainstem
areas (i.e., locus coeruleus and raphe); modulate nociceptive sensitivity primarily
associated with anxiety- and stress-like states[24]

When opioids attach to these opioid receptors, pain messages sent from the body through
the spinal cord to the brain are blocked and an individual experiences a sense of
alleviation.[22] In this study, the opioid receptor we were focused on was the μ-opioid
receptor, since it is the key receptor for analgesia.
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1.1.5. Common Uses of Opioids
1.1.5.1. Pain Management. Opioids are medications most commonly prescribed
by physicians to treat acute or chronic pain, whether it be moderate or severe.[22] They are
frequently utilized for chronic headaches and backaches, post-operative pain, pain
associated with cancer, and injuries resulting from playing sports, falls, and auto
accidents.[22]
1.1.5.2. Cough Suppression. When it comes to coughs, many of which are the
result of infections of the upper and lower airways, asthma, chronic obstructive pulmonary
disease (COPD), lung cancer or lung metastases, interstitial pulmonary processes (e.g.,
lymphatic tumor spread or pulmonary edema), gastroesophageal reflux, aspiration, or a
side effect of certain drugs, opioids are understandably the only effective centrally acting
anti-tussive drugs on the market.[25] This class of medication is believed to work by
suppressing the brainstem cough center through μ- and κ-opioid receptor agonism.[25]
Opioids are typically used as a first-line treatment option for severe coughs.[25] Three of
the most common opioids prescribed to individuals with distressing coughs are codeine,
dextromethorphan, and hydrocodone.[25] Nevertheless, each comes with its own set of side
effects, which includes but is not limited to sedation, constipation, and nausea.[25]
1.1.5.3. Chronic Diarrhea. Through clinical experience, it has been found that
opioids, particularly opioid agonists, are an effective treatment option for people
experiencing chronic diarrhea.[26] Loperamide, also known as Imodium®, is a peripherally
acting opioid that is often recommended as a first-line therapy due to the fact it does not
cause harsh side effects, like sedation and addiction.[26] Other opioids, including
diphenoxylate-atropine, more commonly known as Lomotil®, are also effective at treating
8

chronic diarrhea, but they have the potential of being habit forming and are associated with
a variety of adverse effects, such as sedation, dizziness, and dry mouth.[26] Opioids other
than loperamide should only be used for more refractory cases of chronic diarrhea.[26]
1.1.5.4. Anesthetics. According to the Journal of Pain and Symptom Management,
opioids are widely used in the practice of anesthesia.[27] A number of opioids are used for
preanesthetic medication, systemic and spinal analgesia, supplementation of general
anesthetic agents, as well as primary anesthetics.[27] Opioids used as primary anesthetics
are commonly utilized during major surgical operations involving patients with
cardiovascular disease.[27] This form of anesthetic helps to prevent the occurrence of
cardiac depression.[27] Examples include sufentanil, alfentanil, remifentanil, and
fentanyl.[28]

1.1.6. Adverse Effects of Opioids
1.1.6.1. Respiratory Depression. Although opioids can effectively relieve pain
and discomfort, they do pose some notable risks and can be extremely addictive.[22]
Addiction is especially of concern for people taking opioids in order to manage chronic
pain over an extended period of time.[22] These critical side effects limit their safety and
utility. One of the most life-threatening side effects associated with opioids is respiratory
depression.[29] When taken, opioids induce profound respiratory changes in the body (e.g.,
sleep apnea and hypoventilation), which can cause complete respiratory arrest, especially
if a person overdoses.[29] Opioids bind to MORs in the brain and inhibit the body’s
respiratory circuits, as well as depress breathing by affecting important respiratory
structures of the brainstem.[29] Suppression of these respiratory circuits and structures
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induces respiratory depression by lowering the body’s respiratory rate and
chemosensitivity, the brain’s ability to detect changes in carbon dioxide (CO2) levels.[29,30]
1.1.6.2. Constipation. Opioid drugs are known to cause opioid-induced
constipation (OIC).[31] Opioids inhibit gastric emptying and promote peristalsis in the
gastrointestinal (GI) tract, thus causing increased absorption of fluid in the body.[31] As a
result of lower levels of fluid in the intestines, stool becomes hardened, oftentimes leading
to constipation.[31] Many patients who experience OIC report straining and are unable to
fully empty the rectum during defecation.[31] Additionally, opioids have been found to
impair the defecation reflex, which in turn leads to anal sphincter dysfunction and anal
blockage.[31] Likewise, opioids cause a decrease in pancreatic juice and bile emptying,
resulting in delayed digestion and contributing to the emergence of constipation.[31]
1.1.6.3. Sedation. According to the Clinical Journal of Oncology Nursing, opioidinduced sedation manifests in 20-60% of patients taking opioids.[32] Sedation is typically
defined as depression of brain function due to a medication that results in sleepiness,
drowsiness, fatigue, slowed brain activity, reduced wakefulness, and impaired
performance.[32] Although sedation is a prevalent side effect of opioid analgesics, its exact
mechanism remains elusive.[32] So far, scientists are aware that opioids bind to opioid
receptors in the central nervous system (CNS) and inhibit the firing of certain neurons.[32]
The impact of opioids at these receptors hinders the brain’s arousal mechanism and
decreases content processing, thus contributing to decreased wakefulness and slowed
interpretation of the environment.[32]
1.1.6.4. Tolerance. In regard to drugs, tolerance is defined as a decrease in effect
of a particular substance following prolonged administration, thus resulting in a reduction
10

in potency.[33] This requires a person to need more of the drug in order to generate the same
effect.[33] The development and extent of an individual’s tolerance are correlated to the
drug’s interaction with opioid receptors, as well as its dose and frequency of
administration.[33] There are a variety of mechanisms that impact opioid tolerance, such as
upregulation of drug metabolism (i.e., metabolic tolerance), desensitization of receptor
signaling, and downregulation of receptors.[33] Initiation of compensatory/opponent
processes may also impact tolerance at a behavioral level.[33] Although analgesic tolerance
can often be overcome by simply increasing the therapeutic dose, this is not always a safe
and effective tactic because of other pharmacological effects, like constipation.[33] In
addiction medicine, tolerance strongly influences dependence and abuse liability.[33]
1.1.6.5. Abuse Liability. Abuse liability refers to the tendency of a drug to be
utilized for non-medical purposes (i.e., recreationally) as a result of the substance’s
underlying psychoactive effects, like euphoria and sedation.[34] Not only is abuse liability
dependent on a drug’s properties (e.g., neurochemical effects on the brain, formulation,
and pharmacokinetics), but it is also contingent on the population being studied; this may
incorporate age, vulnerability to addiction, and psychiatric and physical health
morbidities.[34] Moreover, medications have the ability to cause cognitive effects through
direct (e.g., crossing the blood-brain barrier) and indirect (e.g., peripheral mechanisms in
the body) effects on the brain.[34] Over the years, scientists have found several brain
mechanisms to be associated with abuse liability: (1) direct effects on the brain’s reward
pathway (prefrontal cortex and ventral striatum, also known as the nucleus accumbens),
(2) indirect effects on stress-related neuronal pathways (amygdala), and (3) activation of
the ventral tegmentum and amygdala via exposure to drug-related cues.[34] Each one of
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these circuits are controlled by the neuromodulatory effects of dopamine, GABA, and
glutamate, as well as the nicotinic, opioid, and cannabinoid systems of the CNS.[34]

Figure 2
Notable Structures and Pathways of the Brain

Note. One of the most important pathways when it comes to abuse liability is the
mesolimbic dopaminergic pathway, the major reward circuit in the brain. During rewarding
experiences, like drinking alcohol or using drugs, the dopamine system is stimulated,
causing an abundance of dopamine to be released and pleasurable feelings to be felt
throughout the body. This pathway contributes to the rewarding and reinforcing effects of
opioid consumption, which in turn can lead to misuse, abuse, and addiction.[35,36]
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1.1.7. Opioid Use Disorder (OUD)
Opioid use disorder (OUD) is defined as a “problematic pattern of opioid use that
leads to serious impairment or distress.”[37] The Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-5), published in 2013, put together a list of 11
symptoms that help diagnose OUD.[37,38] Severity is based on the number of symptoms a
person presents within a 12-month period of time—mild (2-3 symptoms), moderate (4-5
symptoms), or severe (6 or more symptoms).[37] The DSM-5’s criteria for diagnosis of
OUD is as follows:

Table 2
DSM-5’s Criteria for Diagnosis of OUD
LOSS OF CONTROL
1

Opioids are often taken in larger amounts or over a longer period than
was intended.

2

There is a persistent desire or unsuccessful efforts to cut down or
control opioid use.

3

A great deal of time is spent in activities necessary to obtain the opioid,
use the opioid, or recover from its effects.

4

Craving, or a strong desire or urge to use opioids.

SOCIAL PROBLEMS
5

Recurrent opioid use resulting in a failure to fulfill major role
obligations at work, school, or home.

6

Continued opioid use despite having persistent or recurrent social or
interpersonal problems caused or exacerbated by the effects of opioids.

7

Important social, occupational, or recreational activities are given up or
reduced because of opioid use.
13

RISKY USAGE
8

Recurrent opioid use in situations in which it is physically hazardous.

9

Continued opioid use despite knowledge of having a persistent or
recurrent physical or psychological problem that is likely to have been
caused or exacerbated by the substance.

PHARMACOLOGICAL PROBLEMS
10

Tolerance, as defined by either of the following:

a. A need for markedly increased amounts of opioids to achieve
intoxication or desired effect.

b. A markedly diminished effect with continued use of the same
amount of an opioid.

Note: This criterion is not considered to be met for those taking opioids
solely under appropriate medical supervision.
11

Withdrawal, as manifested by either of the following:

a. The characteristic opioid withdrawal syndrome.
b. Opioids (or a closely related substance) are taken to relieve or
avoid withdrawal symptoms.

Note: This criterion is not considered to be met for those individuals
taking opioids solely under appropriate medical supervision.
Note. Source: Diagnostic and Statistical Manual of Mental Disorders: DSM-5. (Fifth
Edition). (2013). American Psychiatric Association.[39]

Along with the DSM-5’s criteria for diagnosis of OUD, clinicians may require
patients showing symptoms of problematic opioid usage to undergo drug testing. This may
include the collection of matrices, the biological material used for analysis in a drug test.[40]
Examples of matrices include blood, urine, oral fluid (spit/saliva), hair, nails, sweat, and
14

exhaled breath samples.[40] Currently, urine is the most commonly used biological
specimen when it comes to drug and alcohol testing in a clinical setting.[40] Nevertheless,
these types of drug tests are classified as presumptive tests and only provide preliminary
evidence regarding the absence or presence of drugs or metabolites in a sample (often used
for screening purposes).[40] Generally, presumptive testing utilizes immunoassay
technology.[40] Immunoassays use antibodies formulated to bind to certain drugs,
metabolites, or a class of compounds in a given sample.[40] If there are no drugs or drug
byproducts present in the sample, then the antibodies will bind to a conjugate compound
and produce a colored line in the test readout area.[40] Since presumptive tests may display
less accurate results because of fast turnaround times and are susceptible to tampering,
definitive testing can also be used to detect specific substances in samples.[40] Definitive
testing typically incorporates gas or liquid chromatography in combination with mass
spectrometry.[40] Chromatography is used to separate a specimen into its individual
components, whereas mass spectrometry helps to identify those parts.[40] These definitive
techniques often help to confirm and quantify presumptive positive and negative drug test
results.[40]
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1.1.7.1. Current FDA-Approved Treatments for OUD.

Table 3
Pharmacological Treatments for OUD
Name

Function

Methadone

Opioid full agonist

Structure

[41]

Buprenorphine

Opioid partial agonist

[42]

Naltrexone

Opioid antagonist

[43]

Note. Name, function, and structure of current pharmacological treatments for OUD
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1.1.8. Opioid Addiction Research in the Keck Animal Behavior Lab
1.1.8.1. Background. Opioid analgesics are crucial therapeutic techniques for the
management of acute and chronic pain.[3] However, their side effects—respiratory
depression, constipation, sedation, tolerance, and abuse liability—limit their safety and
utility.[3] Therefore, in order to provide patients with safer analgesic options, it is
imperative for researchers to identify new pharmacotherapeutic strategies to treat pain.[3]
Currently, scientists are aware that activation of the µ-opioid receptors (MORs) in
the central and peripheral nociceptive pathways help to mediate opioid analgesia, as well
as their side effects.[3] Likewise, antinociception can be attained through selective
enhancement of gamma-aminobutyric acid (GABA) signaling at ionotropic GABA type A
(GABAA) receptors.[3] The GABAA receptor has six known α subunits, denoted as α1, α2,
α3, α4, α5, and α6.[3] GABAA’s α2 and α3 subunits (α2/α3GABAA) are co-expressed with
MORs in the dorsal horn spinal pathways, a neuronal pathway important to nociceptive
transmission.[3] The dorsal horn functions as an intermediary processing center comprised
of a complex network of excitatory and inhibitory interneurons, along with projection
neurons that are in charge of transmitting processed somatosensory information from the
spinal cord to the brain.[44] Recent work in our lab and with collaborators has determined
that α2/α3GABAA can be selectively targeted with novel imidazodiazepine positive
allosteric modulators (PAMs), like our drug of interest, MP-III-024, which produces
antinociceptive effects with limited behavioral disruption.[3,45] GABAA PAMs facilitate the
action of GABA by increasing the rate of channel opening, as well as enhancing receptor
affinity for GABA.[3]
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Recently, Mohammad Atiqur Rahman, one of my fellow graduate students at
Rowan University, et al. showed that MP-III-024 co-administered with morphine produces
synergistic antinociceptive and antihyperalgesic effects in rodent models.[46] He
demonstrated this using two techniques: hot plate and von Frey testing. During hot plate
testing, antinociception was assessed using a hot plate analgesia meter.[46] Before
experimentation, animals were injected with either morphine, MP-III-024, or a drug mix,
consisting of morphine and MP-III-024.[46] Certain behavioral changes, such as paw licking
or fluttering and/or jumping from the hot plate surface, after placing the animal on the hot
plate were recognized as a pain response.[46] In comparison, during von Frey testing,
antihyperalgesic effects were studied following inflammation of the right hind paw evoked
by zymosan A, a substance often used to induce experimental sterile inflammation.[46,47]
The non-injected left hind paw was used as the control.[46] 24 hours after the zymosan A
injection, mechanical sensitivity was assessed through the use of von Frey filaments of
increasing stiffness following an injection of either morphine alone, MP-III-024 alone, or
the morphine + MP-III-024 drug mix at varying ratios.[46] The mid plantar surface of each
animal’s right and left hind paws was poked with these thin, plastic filaments in order to
determine the threshold that produces a hind paw withdrawal response.[46] A positive
response was considered to be any type of paw withdrawal reflex after being poked by one
of the filaments; mechanical sensitivity of this testing was defined as the minimum force
necessary to elicit paw withdrawal behavior.[46]
Rahman et al. demonstrated that morphine was a potent analgesic in both the hot
plate and von Frey testing procedures.[23] However, MP-III-024 only produced analgesia
in the von Frey test.[23] On the hot plate assay, MP-III-024 did not show significant
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analgesic effects at any of its administered doses (3.2, 10, and 32 mg/kg).[23] Contrastingly,
on the von Frey assay, morphine and MP-III-024 displayed effectiveness simultaneously,
with their dose effect curves being parallel (p < 0.05).[23] Moreover, when morphine was
given in combination with MP-III-024, leftward shifts in the dose-response function for
both assays were observed.[23] Therefore, Rahman et al. was able to deduce that the
analgesic effect of each of the drug mixes was better than the effect produced by morphine
alone, with respect to antinociception and antihyperalgesia.[23] Additionally, graphical
analysis of each mixture indicated that morphine in combination with MP-III-024 produced
superadditive, or synergistic, effects.[23] The synergistic effects of morphine + MP-III-024
suggest that this new drug combination may be used as an analgesic that requires a lower
dosage in order to yield its desired effect.[23] Still, the safety profile of this combination
needs to be studied, which brings us to my research.
1.1.8.2. Research Goal. Thanks to the groundbreaking research conducted by
Rahman et al., we now know that morphine in combination with MP-III-024 produces a
superadditive, or synergistic, effect in models of pain. With this newfound information,
two questions arise: (1) Does this mean that MP-III-024 is universally synergistic with
morphine? (2) Does this drug mix have a synergistic side effect profile, as well? Since
morphine + MP-III-024 had a synergistic analgesic property, we would predict that MPIII-024 enhances all of morphine’s side effects, whether desirable or undesirable. In order
to determine if MP-III-024 is universally synergistic with morphine, we have observed how
varying doses (3.2, 10, and 32 mg/kg) and combination drug ratios (1.0:0.31, 1.0:0.94, and
1.0:2.8 morphine to MP-III-024, respectively) of morphine, MP-III-024, and morphine +
MP-III-024 affect the behavior of mice trained to self-administer palatable food rewards.
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The goal of this experiment is to find new drug types that can be paired with opioids to
improve analgesia with fewer side effects and lower rates of dependence and addiction.

1.2. Part 2 – Alcohol

1.2.1. What is Alcohol?
Alcohol, also known as ethanol or ethyl alcohol, is the main ingredient found in
beer, wine, and spirits.[48] It is considered to be a sedative-hypnotic drug and is classified
as a depressant, which means it depresses the central nervous system (CNS) at high doses
and slows down vital bodily functions.[48,49] Usually, the amount of alcohol an individual
consumes determines its effect on the body.[49] At lower doses, alcohol acts as a stimulant
and causes feelings of euphoria and wellbeing, talkativeness, increased alertness, and so
on.[49,50] Typically, the majority of people who drink alcohol are looking to obtain its
stimulant effect, rather than its depressant effect.[49] However, if a person consumes more
than his or her body can accommodate in a single session, alcohol’s depressive effects,
such as drowsiness, respiratory depression, slurred speech, unsteady movement, decreased
reaction time, and distortion in judgment and rationality, start to ensue.[48,49]
Alcohol is formed when yeast ferments (i.e., breaks down without oxygen) the
sugars in various foods, most notably fruits, vegetables, and grains.[48] For example, wine
comes from the sugar found in grapes, beer is made from the sugar in malted barley (a kind
of grain), cider originates from the sugar produced by apples, and vodka is the product of
fermented sugar in potatoes, beets, and other plants.[48] Although there are many types of
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alcohol out there (e.g., isopropyl, methyl, and ethyl), the only kind of alcohol that can be
consumed by humans and therefore the one found in all our alcoholic beverages is ethyl
alcohol, more commonly known as ethanol.[49]

Figure 3
Chemical Structure of Ethanol

[51]

1.2.2. History of Alcohol
For thousands of years, fermented grain, fruit juice, and honey have been utilized
to produce alcohol.[49] There is evidence to suggest that fermented beverages existed in
early Egyptian civilization, as well as China around 7000 BCE.[49] Similarly, an alcoholic
beverage known as sura, which came from distilled rice, was consumed between 3000 and
2000 BCE.[49] As early as 2700 BCE, there is also record of the Babylonians worshipping
a wine goddess; and in Greek literature, which dates back thousands of years, there is
warnings of excessive drinking.[49] In Greece, one of the first noted alcoholic beverages
was mead, a fermented drink produced from the fermentation of honey and water.[49]
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Additionally, there is evidence to suggest that a number of Native American
civilizations developed alcoholic beverages in pre-Columbian times.[49] A large sum of the
fermented beverages produced in the Andes region of South America were made from
corn, grapes, and apples, referred to as “chicha.”[49] Likewise, in the 1500s, alcohol, often
called spirits, was commonly used for medicinal practices.[49] At the start of the 1700s, the
British parliament passed a law encouraging people to use grain in order to distill spirits.[49]
As a result of this request, cheap spirits filled the British markets and reached peak sale
mid-eighteenth century.[49] During this time, one of the most popular spirits among the
British people was gin.[49] Due to its high consumption rate throughout this period, gin is
often blamed for commencing widespread alcoholism in Britain.[49]
Attitudes towards alcohol began changing in the nineteenth century with the
temperance movement promoting moderate use of alcohol in order to halt the spread of
alcoholism.[49] This change in attitude towards fermented beverages ultimately became a
driving factor in the push for total prohibition.[49] The prohibition movement took the
United States by storm and in 1920, the United States’ government passed a law prohibiting
the manufacture, sale, import, and export of all alcoholic beverages.[49] This strict law
forbidding the consumption of intoxicating liquors prompted the illegal alcohol trade and
by 1933, the prohibition of alcohol was repealed.[49] More recently, in 1971, as part of the
Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), the National
Institute on Alcohol Abuse and Alcoholism (NIAAA) was founded to act as the primary
federal agency overlooking alcohol abuse and alcoholism in the United States.[52] The
NIAAA also funds many research efforts focused on combating conditions, like alcohol
use disorder (AUD).[52]
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1.2.3. The Pharmacokinetics of Alcohol
To date, alcohol is one of the most widely consumed legal drugs around the
world.[53] In regard to its pharmacokinetics, alcohol is absorbed into the bloodstream
through small blood vessels located in the walls of the stomach, as well as the small
intestine.[49] After an individual consumes an alcoholic beverage and a substantial amount
of oral absorption has taken place, alcohol begins to travel from the stomach to the brain,
where it begins initiating its stimulatory then depressant effects, if the person continues
drinking.[49] Along with being absorbed by the stomach and the small intestine, alcohol is
also taken up by the liver, where it is metabolized and converted into acetaldehyde, a very
toxic byproduct of alcohol, then acetate.[49,54] Eventually, acetate leaves the liver and is
converted into CO2 and H2O by means of the Krebs cycle.[54] Nevertheless, the liver only
has the ability to metabolize a certain amount of alcohol at a time, thus leaving the
remainder to circulate throughout the body and cause adverse effects.[49] Moreover, when
the amount of alcohol found in a person’s blood surpasses a certain concentration, the
respiratory system begins slowing down remarkably and adverse effects, such as coma and
death, can result if oxygen is unable to reach the brain.[49] In most people, though, after a
day or night of drinking, the excess alcohol left in the body that is not oxidatively
metabolized by the liver is removed unchanged by means of excretion via the kidneys
(urine), lungs (breath), or skin (sweat) and alcohol’s side effects cease.[54]
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Figure 4
Metabolism of Alcohol in the Liver

Note. In the first step, alcohol (i.e., ethanol) is metabolized by the enzyme, alcohol
dehydrogenase (ADH), and is converted into a highly toxic substance and known
carcinogen, acetaldehyde. Then, in the second step, acetaldehyde is metabolized by the
enzyme, aldehyde dehydrogenase (ALDH), to a less active byproduct, acetate, which is
eventually broken down into CO2 and H2O, allowing for easy excretion from the body.
Other enzymes, including cytochrome P450 2E1 (CYP2E1) and catalase, are also involved
in this process, helping to break down alcohol to acetaldehyde. Interestingly, CYP2E1
tends to only be active after an individual has consumed large quantities of alcohol.[55]
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1.2.4. Short- and Long-Term Effects of Alcohol

Table 4
Side Effects of Alcohol Usage
Short-Term Effects:

Long-Term Effects:

•

Slurred speech

•

Family problems/broken relationships

•

Drowsiness

•

Loss of productivity in the workplace

•

Nausea

•

Unintentional injuries: car crashes,

•

Vomiting

•

Diarrhea

•

Headaches

•

Difficulty breathing

•

Alcohol poisoning

•

Distorted vision and hearing

•

High blood pressure, stroke, or other

•

Impaired judgment

•

Decreased perception and

•

Liver disease

coordination

•

Cancer of the mouth and throat

•

Blackouts (memory lapses)

•

Nerve damage

•

Unconsciousness

•

Permanent brain damage

•

Coma

•

Sexual dysfunction

•

Anemia

•

Vitamin B1 deficiency

•

Ulcers

•

Gastritis

•

Malnutrition

falls, burns, drownings
•

Intentional injuries: firearm injuries,
sexual assaults, domestic violence

heart-related diseases
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[49]

1.2.5. Alcohol Use Disorder (AUD)
According to the National Institutes of Health (NIH), alcohol use disorder (AUD)
is defined as a “chronic relapsing brain disease that causes a person to drink compulsively
despite adverse consequences to daily life and overall health.”[56] The Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published in 2013, put
together a list of 11 symptoms that help diagnose AUD.[38] Severity is based on the number
of symptoms a person presents within a 12-month period of time—mild (2-3 symptoms),
moderate (4-5 symptoms), or severe (6 or more symptoms).[57] The DSM-5’s criteria for
diagnosis of AUD is as follows:

Table 5
DSM-5’s Criteria for Diagnosis of AUD
LOSS OF CONTROL
1

Alcohol is often taken in larger amounts or over a longer period than
was intended.

2

There is a persistent desire or unsuccessful efforts to cut down or
control alcohol use.

3

A great deal of time is spent in activities necessary to obtain alcohol,
use alcohol, or recover from its effects.

4

Craving, or a strong desire or urge to use alcohol.

SOCIAL PROBLEMS
5

Recurrent alcohol use resulting in a failure to fulfill major role
obligations at work, school, or home.

6

Continued alcohol use despite having persistent or recurrent social or
interpersonal problems caused or exacerbated by the effects of alcohol.
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7

Important social, occupational, or recreational activities are given up or
reduced because of alcohol use.

RISKY USAGE
8

Recurrent alcohol use in situations in which it is physically hazardous.

9

Alcohol use is continued despite knowledge of having a persistent or
recurrent physical or psychological problem that is likely to have been
caused or exacerbated by alcohol.

PHARMACOLOGICAL PROBLEMS
10

Tolerance, as defined by either of the following:
a. A need for markedly increased amounts of alcohol to achieve
intoxication or desired effect.
b. A markedly diminished effect with continued use of the same
amount of alcohol.

11

Withdrawal, as manifested by either of the following:
a. The characteristic withdrawal syndrome for alcohol.
b. Alcohol (or a closely related substance, such as a
benzodiazepine) is taken to relieve or avoid withdrawal
symptoms.

Note. Source: Diagnostic and Statistical Manual of Mental Disorders: DSM-5. (Fifth
Edition). (2013). American Psychiatric Association.[39]

Similar to the preceding section discussing the various drug testing methods for
people suffering from OUD, along with utilizing the DSM-5’s checklist for diagnosing
AUD, clinicians may require patients showing symptoms of concerning and problematic
alcohol usage to undergo routine blood, urine, or other lab tests in order to assess the
severity of their alcohol consumption. These tests may again require the use of presumptive
(e.g., immunoassay) and/or definitive (e.g., chromatography/mass spectrometry) drug
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testing techniques to determine the presence or absence of alcohol or its metabolites in a
given sample, as well as the alcohol concentration within a sample.[40]

1.2.5.1. Current FDA-Approved Treatments for AUD.

Table 6
Pharmacological Treatments for AUD
Name

Function

Structure

Disulfiram

Acetaldehyde
dehydrogenase antagonist

[58]

Naltrexone

Opioid antagonist

[43]

Acamprosate

Mechanism of action is
unclear; believed to act as a
GABA receptor agonist
and glutamate receptor
antagonist
[59,60]

Note. Name, function, and structure of current pharmacological treatments for AUD
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[61]

Non-FDA approved medications for AUD include nalmefene (which is approved
in Europe for AUD), gabapentin, topiramate, baclofen, and ondansetron.[62] The American
Psychiatric Association (APA) guidelines recommend naltrexone and acamprosate be
offered to patients as first-line treatment options for individuals suffering from moderate
to severe AUD.[62] Second-line treatment options may incorporate the administration of
disulfiram, topiramate, and gabapentin if patients are intolerant or have not responded well
to naltrexone or acamprosate, or if they prefer one of these second-line drugs over the firstline options.[62] Likewise, naltrexone should not be administered to patients diagnosed with
severe hepatic impairment, since it can cause hepatotoxicity, or concomitant opioid use.[62]
Similarly, acamprosate should not be taken by people who have severe renal impairment,
since this drug is unable to be metabolized by the liver and is excreted renally.[62] The APA
has not yet acknowledged the use of baclofen or ondansetron for AUD.[62]

1.2.6. Alcohol Addiction Research in the Keck Animal Behavior Lab
1.2.6.1. Background. Along with drug addiction, alcoholism is a major health
problem in the United States, as well as on a global level. Although there are treatment
options currently on the market to help combat alcohol use disorder (AUD), the side effects
associated with these medications are not always desirable and their success rates are often
low due to poor compliance.[63] Therefore, non-pharmacological techniques, like
behavioral treatments (e.g., alcohol counseling or talk therapy) or mutual-support groups
(e.g., Alcoholics Anonymous, also known as AA), are typically the first and only treatment
methods explored by individuals suffering from AUD.[52,57] Depending on the individual,
these non-pharmacological approaches are not always successful and pose a risk of relapse
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occurring without the implementation of drug intervention. With AUD being such a
prominent health issue around the world, there needs to be pharmacological treatment
options available to people diagnosed with AUD that are not only efficacious but have
limited adverse effects, thus resulting in increased patient compliance and potentiating a
promising, new cure.
One of the main hurdles that comes with creating a drug for individuals suffering
from alcoholism is knowing where exactly in the brain alcohol targets. In the past, scientists
believed that alcohol acted as a membrane disruptor that inflicted a generalized effect all
over the brain.[64] However, scientists now know that there are actually specific structures
in the brain that alcohol targets, the most notable being γ-aminobutyric acid (GABA)
receptors, glutamate receptors, and the nucleus accumbens.[64] The nucleus accumbens is a
pivotal component of the brain’s mesolimbic pathway, the major dopaminergic pathway
that gets stimulated during rewarding experiences, like using drugs or drinking alcohol.[65]
Since alcohol has been found to have a profound effect on dopamine release in the brain’s
reward center, thus inducing its stimulating, pleasurable effects, it is plausible to
hypothesize that medications that target dopamine receptors may be up-and-coming
treatment options for people suffering from AUD.
When dopamine is released, it acts on receptor proteins termed the dopamine
receptors. There are five dopamine receptors identified including dopamine D1 receptor
(D1R), dopamine D2 receptor (D2R), dopamine D3 receptor (D3R), dopamine D4 receptor
(D4R), and dopamine D5 receptor (D5R). So far, there have been several lines of evidence
indicating that pharmacologically targeting D4R, may be advantageous when it comes to
substance use disorders, such as AUD.[66] Preliminary data utilizing the full D4R antagonist,
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CAB-01-019, has shown promising results in rodent models of cocaine addiction.[66]
Through behavioral analysis it was revealed that injections of CAB-01-019 prior to
experimentation attenuated cocaine self-administration at all three of the drug’s tested
dosages (5, 15, and 30 mg/kg).[66] Cocaine is a highly addictive stimulant drug that, similar
to alcohol, has been found to have a profound effect on the dopaminergic receptors of the
brain.[67,68] In conjugation with these findings of CAB-01-019 dose-dependently decreasing
cocaine intake, as well as the commonalities between cocaine and alcohol’s effect on
dopamine, it is assumed that CAB-01-019 will also attenuate drug-taking and -seeking
behaviors in animal models of alcohol addiction and prove to be a promising new avenue
for AUD medication development in the near future.[66]
1.2.6.2. Research Goal. In order to determine if CAB-01-019 is a good drug
candidate for treating AUD, we must first explore how behaviorally disruptive it is. In the
past, antagonism of the D4R was found to disrupt processes involved with memory and
cognition, therefore indicating that it may be important to maintain a level of D4R
activation through partial agonism rather than full antagonism.[66] A reliable method of
testing behavioral disruption is through the use of operant responding by means of selfadministration of palatable food rewards. Thus, the goal of this experiment is to study the
effects that CAB-01-019 evokes during sessions of self-administration in mice trained to
self-administer palatable food rewards. The results of this testing will be used as 1) a critical
control for alcohol tests, separating alcohol-specific effects from non-specific behavioral
or appetitive effects, and 2) a training precursor for ethanol self-administration. Future
research plans include additional testing to determine if CAB-01-019 affects operant
alcohol self-administration in mice.
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Chapter 2
The Effects of Morphine and MP-III-024 Co-Administration on Food SelfAdministration and Open Field Testing

2.1. Abstract
Each year, millions of people across the globe suffer from opioid use disorder
(OUD). Opioid misuse, abuse, and addiction, along with overprescribing are responsible
for fueling the Opioid Epidemic, a major health crisis in the United States. Thus, there is a
dire need for new treatment techniques for pain management that are less addictive and
less subject to misuse and abuse. In previous work, our lab determined that the novel
imidazodiazepine, MP-III-024, when co-administered with the opioid analgesic, morphine
(in 1.0:0.31, 1.0:0.94, or 1.0:2.8 ratios of morphine:MP-III-024), produced synergistic
effects in models of analgesia and antinociception. In this study, the combination effects
of morphine and MP-III-024 were analyzed in food self-administration and open field
testing, tests representative of a subset of opioid side effects. Based on prior research
studies, we hypothesized that morphine + MP-III-024 would produce synergistic effects in
these behavioral tests. The results of our self-administration testing demonstrated that
morphine co-administered with MP-III-024 had statistically indistinguishable effects
compared to morphine alone; but, adding MP-III-024 to morphine did not make morphine
more disruptive in regard to operant responding. In open field testing, however, our
1.0:0.94 morphine:MP-III-024 ratio attenuated morphine-induced hyperlocomotion and
was found to be statistically less than morphine alone, a subadditive (anti-synergistic)
effect. With these findings, we now know that morphine and MP-III-024 are not universally
32

synergistic. Therefore, this drug mix may be able to produce more potent analgesia with
reduced risks of opioid-induced side effects, potentially increasing the safety of opioid
analgesia treatments.

2.2. Introduction
Opioid misuse, abuse, and addiction are major health problems around the globe.
In 2019, in the United States alone, approximately 50,000 individuals died from opioid
overdoses.[69] Since opioids are so addictive, many people who do not take them as
prescribed or use them recreationally often develop a chronic and relapsing illness known
as opioid use disorder (OUD).[70] In simple terms, OUD is a physical and psychological
dependence on opioids frequently characterized by symptoms of uncontrollable cravings
and the inability to control usage.[70] Likewise, OUD increases the likelihood of disability,
overdose, and in some cases, death.[70]
To better understand the purpose of this study, it is important to know some
background information regarding opioids. Opioids are derived from the opium poppy
plant, known scientifically as Papaver somniferum.[71,72] However, nowadays, many
opioids are synthetically formulated in a lab by scientists.[72] These types of substances are
highly potent and effective analgesics, commonly used to treat moderate to severe
pain.[71,72] Nevertheless, opioids are highly addictive due to their euphoric effects and as a
result of this are often abused.[72] To date, one of the most dangerous and addictive opioids
is the illicit drug, heroin.[72] Common prescription opioids include codeine, fentanyl,
hydrocodone

(Vicodin®),

morphine,

oxycodone

oxymorphone.[72]
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(OxyContin®,

Percocet®),

and

Opioids affect the body in many different ways. Although they are often beneficial
when it comes to reducing pain triggered by surgery, trauma, disease, and other painful
conditions, they come with a lot of risks.[70,73] Approximately 80% of the people who take
opioids have experienced at least one adverse event, with the most common being
gastrointestinal problems (e.g., constipation, nausea, and vomiting).[74] Important side
effects include respiratory depression and hypoxia, which is the reason people die of
overdoses, infections of the heart, lungs, and liver, and tolerance, dependence, and
addiction.[72,75] These side effect risks tremendously increase when taking illegal,
unregulated drugs, like heroin.[72] For example, new diagnoses of Hepatitis C, an infection
that attacks the liver, are often linked to people who inject drugs using contaminated
needles, syringes, or injection equipment.[75] According to the Centers for Disease Control
and Prevention (CDC), opioids, predominantly synthetic opioids, are the main cause of
drug overdose deaths in the United States.[76] Therefore, there is a dire need for new
treatment techniques that are less addictive and subject to misuse and abuse.
In regard to their mechanism of action (MOA), opioids bind to and activate opioid
receptors predominantly found in the central nervous system (CNS), which includes the
brain and spinal cord, and the peripheral nervous system (PNS), as well as other organs in
the body associated with pain and pleasure.[72,46] After attaching to these opioid receptors,
opioids inhibit pain signals being conveyed from the brain to the rest of the body, also
causing large quantities of dopamine to be released, which is the neurotransmitter that helps
mediate pleasure in the brain.[72] Currently, there are four known opioid receptors
designated as mu (µ), kappa (κ), delta (δ), and nociception/orphanin FQ.[46,77] Activation
of µ-opioid receptors (MORs) is responsible for the prototypic opioid effects of analgesia,
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reward, and withdrawal.[77] Additionally, MORs in the CNS are associated with respiratory
depression, analgesia, euphoria, and miosis, and those in the PNS are linked to cough
suppression and constipation.[77]
Scientists are aware that opioid’s analgesic properties can also be attained through
selective enhancement of γ-aminobutyric acid (GABA) signaling at ionotropic GABA type
A (GABAA) receptors.[3] The GABAA receptor has six known α subunits.[3] GABAA’s α2
and α3 subunits (α2/α3GABAA) have been found to be co-expressed with MORs in the
dorsal horn spinal pathways, where they help to mediate the transmission of pain sensory
signals throughout the body.[3] It has been found that α2/α3GABAA can be selectively
targeted with novel imidazodiazepine positive allosteric modulators (PAMs), like our drug
of interest, MP-III-024, which produces antinociceptive effects with limited behavioral
disruption.[3] GABAA PAMs facilitate the action of GABA by increasing the rate of channel
opening, as well as enhancing receptor affinity for GABA.[3]
There are currently three FDA-approved treatments for OUD, which include
methadone, an opioid agonist, buprenorphine, an opioid partial agonist, and naltrexone, an
opioid antagonist.[78] Opioid agonists work by binding and activating opioid receptors, the
same receptors that are activated by the body’s endogenous opioids, β-endorphin, met- and
leu-enkephalins, and the dynorphins.[78,79] In contrast, opioid antagonists block opioid
receptors instead of activating them, thus stopping opioids from producing any effect.[78]
Methadone is a full µ agonist that helps block the euphoric effects of opioid drugs, as well
as minimizes the symptoms caused by opioid withdrawal.[78] Buprenorphine is a partial
agonist, which means that it binds to opioid receptors and blocks the effects of opioid drugs
like methadone; however, it is considered to be a partial agonist because it has high affinity
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for the µ-opioid receptor but low intrinsic activity.[78,80] Nevertheless, buprenorphine still
helps to reduce cravings and withdrawal symptoms.[78] Naltrexone is an antagonist,
meaning it has no intrinsic signaling effects on its own and prevents other opioids from
binding and activating opioid receptors altogether.[78] As a result, if an individual takes
opioids while on naltrexone, the opioids will not produce an effect; although, this drug
should really only be prescribed to people who have completely detoxed from opioids in
order to avoid precipitating withdrawal.[78,81]
Even though there are FDA-approved treatment options out there for people
suffering from OUD, new treatment strategies that reduce opioid exposure need to be
explored, since they may help decrease the likelihood of OUD development. One of the
research objectives of the Keck Animal Behavior Lab is testing new drug combinations
that may help to reduce the doses of clinically prescribed opioids. In this study, we tested
the combination effects of morphine, a µ opioid agonist, and MP-III-024, a novel
imidazodiazepine with PAM effects at α2- and α3-subunit containing GABAA
receptors.[45,46] Our main goal is to find new candidate medications that can be coadministered with opioids to selectively enhance analgesia, reducing the risks of opioidinduced side effects, including opioid addiction.
Thanks to some groundbreaking research conducted by Mohammad Atiqur
Rahman, a recent Rowan University graduate, et al., we know that MP-III-024 coadministered with morphine produces synergistic antinociceptive and antihyperalgesic
effects in mouse models of thermal and inflammatory pain.[46] However, with this
newfound information, an important question arises: Is MP-III-024 universally synergistic
with morphine and, therefore, will morphine/MP-III-024 co-administration produce a
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synergistic side-effect profile as well? Our working hypothesis for these studies is that
because morphine/MP-III-024 co-administration produced synergistic analgesic effects,
we predict that MP-III-024 similarly enhances morphine-mediated side effects. In
pharmacology, synergism (derived from the Greek word “synergos” which means
“working together”) is defined as “an interaction between two or more drugs that causes
the total effect of the drugs to be greater than the sum of the individual effects of each
drug.”[1,82] Synergistic effects can be harmful or beneficial to one’s health.[1]
According to the findings of several other preclinical research studies, it is likely
that morphine and MP-III-014 will have a synergistic side effect profile. Biological data
published by Gueye et al. (2002), Megarbane et al. (2005), and Nielsen and Taylor (2005)
have demonstrated that these two drug classes have synergistic effects in regard to sedation
and respiratory depression when administered concurrently and may contribute to the
chance of fatal overdose.[83,84] There are serious risks associated with the concomitant use
of opioids and benzodiazepines, especially since benzodiazepines are known to enhance
the sedating and respiratory effects of other medications and substances, including full
opioid agonists, which morphine acts as on the µ-opioid receptor.[84] Gueye et al. analyzed
this potentially dangerous synergistic relationship in rodent models.[83] In Gueye et al.’s
study, it was shown that while high doses of the opioid, buprenorphine (30 mg/kg, i.v.),
and the benzodiazepine, midazolam (160 mg/kg, i.p.), alone caused mild but significant
increases in partial pressure of arterial carbon dioxide (PaCO2), when co-administered,
these two drugs promoted rapid, substantial, and prolonged respiratory depression and
hypoxia.[83] Similarly, in Megarbane et al.’s preclinical research study, rodents who
received the opioid, buprenorphine (30 mg/kg, i.v.), co-administered with the
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benzodiazepine, flunitrazepam (40 mg/kg, i.v.), displayed rapid and sustained respiratory
depression.[83] However, that dose of buprenorphine alone had no significant effect on the
animals’ respiration rates.[83] Likewise, investigators, such as Nielsen and Taylor, have
proposed potential mechanisms to explain the synergistic impact that comes with the
simultaneous use of opioids and benzodiazepines. Nielsen and Taylor found that
buprenorphine administered in combination with diazepam seemed to abolish the
protective plateau, or ceiling effect (the optimal effect of a drug; once a therapeutic limit is
achieved, increases in doses may cause side effects but no further beneficial effects), of
buprenorphine, thus resulting in a higher risk of respiratory depression and death.[83.85]
Based on Rahman et al.’s results, as well as Fischer et al.’s research studies
investigating MP-III-024, we hypothesized that the synergistic analgesic effects seen with
morphine and MP-III-024 co-administration result from simultaneous enhancement of
signaling by MORs and α2GABAA and α3GABAA receptors, co-expressed in key
nociceptive pathways in the brain and spinal cord.[45,46] We also hypothesized that
morphine and MP-III-024 co-administration will produce synergistic effects in measures
of undesirable pharmacological responses: opioid side effects. This synergistic side effect
profile is further anticipated based on the results from the three studies discussed above
regarding the negative impacts (i.e., sedation and respiratory depression) associated with
concurrent use of opioids and benzodiazepines. To test our hypothesis, we focused on two
opioid-induced behavioral effects: opioid-induced disruption of food-maintained operant
responding and opioid-induced hyperlocomotion in open field.
In regard to locomotor function, morphine is known to induce hyperactivity in
mice. In fact, most drugs of abuse have been found to have a stimulatory effect on
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locomotor activity in laboratory animals, especially after repeated exposure.[86] In relation
to self-administration, if morphine produces dose-dependent increases in locomotor
activity, then we expect to see a decrease in the number of earned food rewards for
morphine administered alone, as well as the morphine/MP-III-024 combination therapy,
especially if there is a synergistic side effect profile for this drug mix. It is assumed that
with the employment of hyperlocomotion, the animals will be less focused on the task at
hand, that being nose poking for palatable food rewards. As a result of this, we expect to
see dose-dependent decreases in operant response rates for self-administration. When
taking this into consideration, as well as our working hypotheses, we predict that
morphine/MP-III-024 co-administration will synergistically enhance morphine-induced
hyperlocomotion and morphine-induced disruption of palatable food self-administration.
As previously mentioned, morphine is well-characterized to produce dose-dependent
increases in locomotor and disrupt operant responding, thus causing a decrease in operant
response rates and a corresponding decrease in food consumption (i.e., rewards), since the
mice are more preoccupied with moving around than searching for food. If our hypotheses
are correct, MP-III-024 given in combination with morphine, will enhance morphineinduced locomotion which in turn will enhance morphine-induced behavioral disruption,
resulting in a leftward shift on the dose-response curves.
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2.3. Materials and Methods

2.3.1. Drugs
2.3.1.1.

Morphine.

Morphine,

also

known

by

its

scientific

name,

(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12methanobenzofuro[3,2-e]isoquinoline-7,9-diol, is a natural plant alkaloid and is recognized
as the main alkaloid of opium.[87,88] Over the years, chemical manipulations to morphine’s
structure have yielded semi-synthetic opioids, for example heroin, and fully synthetic
opioid compounds.[88] Morphine and other opioid agonists bind to and activate opioid
receptors.[87] Morphine, its metabolites, and other opioid analgesics act as agonists at the
µ-, κ-, and δ-opioid receptors.[88] Activation of these opioid receptors result in the inhibition
of pain signals being sent from nociceptors, specialized peripheral sensory neurons which
warn the brain and spinal cord, specifically the dorsal horn neurons, of damaging or
potentially damaging stimuli to the body.[88,89] This in turn provides a sense of temporary
relief if a person is experiencing pain.
2.3.1.2. MP-III-024. MP-III-024, also known by its scientific name, methyl 8ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate, is an
imidazodiazepine positive allosteric modulator (PAM) at α2GABAA and α3GABAA
receptors in the CNS and PNS.[45] Other research studies have determined MP-III-024 to
be α2GABAA- and α3GABAA-selective over α1GABAA and α5GABAA receptors.[45]
α2GABAA and α3GABAA receptors are thought to mediate the antihyperalgesic effects of
benzodiazepines.[45] α1GABAA receptors are associated with the negative side effects of
benzodiazepines, such as sedation and dependence.[45] α5GABAA receptors are involved in
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certain memory processes impacted by benzodiazepines.[45] MP-III-024 was chosen for this
combination drug study because of its high subtype selectivity, as well as its time course
of action, which aligns well with morphine.[3] More importantly, MP-III-024 has negligible
affinity for opioid receptors.[3]

Table 7
Chemical Structure of Morphine and MP-III-024
Morphine

MP-III-024

[90]

[45]

2.3.2. Drug Dosing

2.3.2.1. Food Self-Administration Drug Dosing. The doses for morphine alone
and morphine + MP-III-024, our combination therapy, were 3.2, 10, and 32 mg/kg, with
the drug mixes being a 1.0:0.31, 1.0:0.94, and 1.0:2.8 ratio of morphine to MP-III-024,
respectively. The drug dosing for MP-III-024 alone had an additional 100 mg/kg dose,
since that set of testing was conducted by Fischer et al. in 2017. MP-III-024 was
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synthesized at the Department of Chemistry and Biochemistry at the University of
Wisconsin-Milwaukee. Morphine was purchased from Henry Schein, Inc. The standard
vehicle for these experiments (including vehicle controls) was 0.5% methylcellulose
dissolved in 0.9% NaCl (physiological saline). Doses were administered to mice via
intraperitoneal (i.p.) injections at a volume of 10 mL/kg. Animal weights were determined
on the morning of designated injection days.

Table 8
Food Self-Administration Drug Dosing for Morphine + MP-III-024
Ratio → 1.0:0.31

Ratio → 1.0:0.94

Ratio → 1.0:2.8

Morphine

MP-III-024

Morphine

MP-III-024

Morphine

MP-III-024

3.2 mg/kg

0.992 mg/kg

3.2 mg/kg

3.008 mg/kg

3.2 mg/kg

8.96 mg/kg

10 mg/kg

3.1 mg/kg

10 mg/kg

9.4 mg/kg

10 mg/kg

28 mg/kg

32 mg/kg

9.92 mg/kg

32 mg/kg

30.08 mg/kg

32 mg/kg

89.6 mg/kg

Note. Food self-administration drug dosing for our combination therapy, morphine + MPIII-024, at the three tested ratios (1.0:0.31, 1.0:0.94, and 1.0:2.8). The ratios were derived
using log-linear interpolation by linear regression based on Rahman et al.’s dose-response
curve results for morphine and MP-III-024.[23]

2.3.2.2. Open Field Drug Dosing. Open field testing used cumulative dosing in
which test subjects were repeatedly administered drug doses of increasing concentrations
and then tested after each incremental dose. Locomotor function can be evaluated through
this type of dosing, which is the side effect of interest during this part of experimentation.
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The doses of morphine, MP-III-024, and morphine + MP-III-024 that were selected were
1.0, 2.2, 6.8, 8.0, and 14.0 mg/kg. Likewise, the ratios of morphine to MP-III-024 that were
tested were 1.0:0.31, 1.0:0.94, and 1.0:2.8.

Table 9
Open Field Drug Dosing for Morphine + MP-III-024
Ratio → 1.0:0.31

Ratio → 1.0:0.94

Ratio → 1.0:2.8

Morphine

MP-III-024

Morphine

MP-III-024

Morphine

MP-III-024

1.0 mg/kg

0.31 mg/kg

1.0 mg/kg

0.94 mg/kg

1.0 mg/kg

2.8 mg/kg

2.2 mg/kg

0.682 mg/kg

2.2 mg/kg

2.068 mg/kg

2.2 mg/kg

6.16 mg/kg

6.8 mg/kg

2.108 mg/kg

6.8 mg/kg

6.392 mg/kg

6.8 mg/kg

19.04 mg/kg

8.0 mg/kg

2.48 mg/kg

8.0 mg/kg

7.52 mg/kg

8.0 mg/kg

22.4 mg/kg

14.0 mg/kg

4.34 mg/kg

14.0 mg/kg

13.16 mg/kg

14.0 mg/kg

39.2 mg/kg

Note. Open field drug dosing for our combination therapy, morphine + MP-III-024, at the
three tested ratios (1.0:0.31, 1.0:0.94, and 1.0:2.8). The ratios were derived using log-linear
interpolation by linear regression based on Rahman et al.’s dose-response curve results for
morphine and MP-III-024.[23]

2.3.3. Animals
Drug-naïve adult male CD-1 mice obtained from Charles River Laboratories were
used for these studies. Prior to this experiment, the animals were not exposed to any kind
of behavioral or pharmacological manipulation, which could potentially skew the data and
results of this study. The mice were albino and therefore had white fur and red eyes. They
weighed anywhere between 30-45 grams; however, their weights often fluctuated due to
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daily fasting. Upon arrival to the vivarium located at Cooper Medical School of Rowan
University (CMSRU), the animals were grouped in fours and housed in standard plexiglass
cages, equipped with food, water, bedding, nestlets, and enviropaks and allowed a twoweek habituation period. Each group of animals was housed in a colony room, also known
as a holding room, with a controlled environment (i.e., temperature, humidity, and
light/dark cycle) when not undergoing testing. Throughout the study, the mice had access
to food when not being fasted and continuous amounts of water. The animals utilized in
this experiment were cared for in accordance with the guidelines of the Institutional Animal
Care and Use Committee of Rowan University and all testing followed the “Guide for the
Care and Use of Laboratory Animals.”[45]

Figure 5
CD-1 Mouse

Note. Picture of a CD-1 mouse, the strain used in these studies
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Mice are often utilized in behavioral testing for a number of reasons. Research
regarding the physiology and treatment of pain often requires subjectively testing animals’
reactions to drugs with abuse liability.[3] In order to test behavioral responses, an intact
nervous system is necessary.[3] Since humans cannot be ethically used for this type of work,
mice are a well-accepted model for studying experimental compounds and provide a
handful of advantages over other animal models.[3] Firstly, mice’s murine central nervous
system (CNS) is comparable to humans, thus allowing the extrapolation of results.[3]
Secondly, because of mice’s small size, smaller amounts of drugs can be used for testing.[3]
Lastly, the complete mouse genome is known, allowing for genetic study and
manipulation.[3] CD-1 mice, specifically, are a very popular strain of mouse for these types
of behavioral studies because they are well-characterized behaviorally and have robust
behavioral responses to analgesics and drugs of abuse.[3] Additionally, CD-1 mice have a
common outbred genetic background, allowing for potential genetic follow-up studies to
be carried out in order to identify genetic variables affecting behavioral and cellular
responses.[3]
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2.3.4. Equipment

2.3.4.1. Operant Chambers. The apparatuses used for the first part of this
behavioral study were operant chambers. Each operant chamber was equipped with a
reward receptacle, also referred to as a liquid dipper, located between two nose poking
response holes. The left nose poke hole was designated the correct hole and when poked,
the animals received a reward, that being food, a mixture composed of 50% vanilla Ensure
and 50% water, for this specific study. Contrastingly, the right nose poke hole was
designated the incorrect hole and when poked, generated an incorrect response reading.
The animals did not receive a reward when the right-side hole was poked. The mice were
trained to nose poke using a fixed ratio—a fixed number of correct nose pokes required to
obtain a programmed reward—or FR, system.[52] We started at an FR 1, meaning one
reward per one nose poke, and increased to an FR 4, meaning one reward per four nose
pokes. Additionally, each chamber consisted of a house light, ventilator fan, and a syringe
pump that assisted with administering the Ensure/water rewards. The operant chambers
were controlled by a PC running MED-PC (MED Associates).
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Figure 6
Operant Chamber

Note. Self-administration operant chamber from the Keck Animal Behavior Lab. The left
hole was designated the correct nose poke hole, while the right hole was designated the
incorrect nose poke hole. A reward receptacle was situated in between the two holes, which
administered the mice their palatable food rewards after correctly responding.
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2.3.4.2. Open Field Chambers. The apparatuses used for the second part of this
behavioral study were open field chambers. Each chamber was grey in color (i.e., opaque)
and approximately 40 cm × 40 cm × 35 cm. The chambers consisted of high walls so that
the mice were unable to escape from the apparatuses during testing. The walls fit into a
slotted base that was detachable for easy cleaning. Each floor insert was also grey in color
and did not consist of any gridlines, unlike some other open field chambers. Rather, the
ANY-maze program that computed all the data from the testing sessions provided the
gridlines for the chambers, as depicted in Figure 7 (B). A camera positioned over top of
each chamber in combination with ANY-maze’s tracking software tracked the individual
mice’s movement and location (center or perimeter) in the chambers throughout the
duration of the experiment.
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Figure 7
Open Field Chambers and ANY-Maze Layout

(B)

(A)

Note. (A) Open field chambers from the Keck Animal Behavior Lab. (B) Open field layout
using the ANY-maze program. Each open field chamber was divided into 16 squares. The
outer 12 squares represented the chamber’s perimeter, as highlighted in green in the above
picture, while the inner four squares represented the chamber’s central region. A camera,
as well as ANY-maze’s tracking software tracked the mice’s movement in the chambers in
order to compare how much time was spent in the perimeter squares versus the inner
squares after drug administration.[52]
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2.3.5. Experimental Procedures
2.3.5.1. Food Self-Administration Procedure. Eight CD-1 mice were trained to
nose poke for diluted Ensure for approximately 1.5 months. Each testing session was 120
minutes, or two hours, and was carried out seven days a week. Once the mice reached a
consistent reward response at an FR 4, the animals were injected on designated injection
days with either morphine or morphine + MP-III-024 and placed in the operant chambers.
The data and results for MP-III-024 were already preestablished by Fischer et al. and thus
the animals were not reinjected with MP-III-024 alone. The drug dose each animal received
was determined using a Latin square design, so that every mouse received each drug or the
vehicle exactly one time; Latin square designs are also useful when it comes to controlling
potential variation between test subjects and their assigned drug doses caused by nuisance
factors dependent on the day. Once in the chambers, the MED-PC program analyzed the
animals’ disruption in food self-administration caused by the drugs. This analysis included
important information, such as number of rewards received and response rates. A “rest”
day was placed in between each injection day, which consisted of regular selfadministration testing (i.e., training). Furthermore, the animals were allowed to eat for two
hours after daily testing sessions, then fasted overnight for ~20 hours for the following,
next day experiment, since food deprivation is known to affect rodents’ responsiveness
toward experimental stimuli. In regard to self-administration, fasting helps to manipulate
animals to work for rewards and establishes levels of motivation.
2.3.5.2. Open Field Procedure. Similar to food self-administration, eight CD-1
mice were used. Before the initiation of the open field testing, drug solutions were
prepared. For the first day of testing, the mice were given an acclimation day. Each mouse
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was placed in an open field chamber for 15 minutes and allowed to explore the testing
apparatus. On the second day of testing, the mice received six i.p. injections of just vehicle.
After each injection, the mice were placed into the open field chambers for 30 minutes and
their locomotor function was recorded and processed by the cameras placed over top of the
chambers and the ANY-maze tracking software installed on one of our computers. For the
last day of testing, each mouse again received six injections, this time consisting of the
incremental drug doses of morphine alone, MP-III-024 alone, or morphine + MP-III-024,
starting with 1.0 mg/kg and ending with 14.0 mg/kg (cumulatively 32 mg/kg). After each
injection, the mice were placed into the open field chambers for 30 minutes and their
behavior and activity were analyzed in order to determine if their locomotor function was
disrupted due to the introduction of morphine, MP-III-024, and/or the drug combination,
morphine + MP-III-024.
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2.4. Data and Results

2.4.1. Food Self-Administration Reward Values

Table 10
Morphine Reward Values

Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg
Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg

Cage 1 Animal 1
100
100
100
32
Cage 2 Animal 1
81
36
0
0

Cage 1 Animal 2
82
60
45
8
Cage 2 Animal 2
87
66
34
0

Cage 2 Animal 3
100
100
91
0

Cage 1 Animal 4
100
100
68
8
Cage 2 Animal 4
100
100
94
15

Table 11
Morphine + MP-III-024 (Ratio → 1.0:0.31) Reward Values

Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg
Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg

Cage 1 Animal 1
100
100
100
0
Cage 2 Animal 1
27
29
75
0

Cage 3 Animal 4
78
61
15
0
Cage 2 Animal 2
60
62
69
0
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Cage 3 Animal 2
100
66
88
0
Cage 3 Animal 3
60
100
43
0

Table 12
Morphine + MP-III-024 (Ratio → 1.0:0.94) Reward Values

Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg
Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg

Cage 1 Animal 1
100
100
100
62
Cage 2 Animal 1
2
81
24
0

Cage 1 Animal 2
100
100
100
38
Cage 2 Animal 2
65
5
100
0

Cage 2 Animal 3
100
100
31
100

Cage 1 Animal 4
32
27
100
29
Cage 2 Animal 4
100
100
100
5

Table 13
Morphine + MP-III-024 (Ratio → 1.0:2.8) Reward Values

Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg
Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg

Cage 2 Animal 1
59
28
29
0

Cage 3 Animal 4
100
90
68
11
Cage 2 Animal 2
100
100
100
0

Cage 3 Animal 2
100
100
56
0
Cage 3 Animal 3
100
49
55
42

Note. Tables 10-13: Self-administration reward values for morphine alone and morphine
in combination with MP-III-024 at varying ratios. The data collected for the vehicle, which
acted as our control, was compared to the animals’ reward values at 3.2, 10, and 32 mg/kg
doses of morphine or morphine + MP-III-024 in order to observe the behavioral disruptions
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induced by morphine and/or the drug mix. The greyed areas on the tables represent
deceased animals or animals removed from the study.

2.4.2. Food Self-Administration Rewards Graph

Figure 8
Morphine and MP-III-024 Self-Administration Rewards Graph

Note. The graph above depicts the food self-administration reward values for morphine and
morphine + MP-III-024, our combination drug therapy. We wanted to know if MP-III-024
would enhance or reduce morphine’s behavioral effects at varying ratios. The x-axis
represents the injected dose of morphine alone or morphine + MP-III-024 (3.2, 10, or 32
mg/kg), as well as our vehicle control, while the y-axis is the number of earned rewards.
Two-way ANOVA revealed that morphine significantly reduced the number of earned
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palatable food rewards, but the drug mix at every tested ratio (1.0:0.31, 1.0:0.94, and
1.0:2.8) did not significantly affect earned rewards in comparison to morphine alone. All
results are presented as means ± SEM.

2.4.3. Food Self-Administration Response Rate Values

Table 14
Morphine Response Rate Values

Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg
Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg

Cage 1 Animal 1
0.092
0.105
0.094
0.018
Cage 2 Animal 1
0.045
0.020
0.000
0.000

Cage 1 Animal 2
0.046
0.033
0.025
0.004
Cage 2 Animal 2
0.049
0.037
0.019
0.000

Cage 2 Animal 3
0.089
0.067
0.051
0.000

Cage 1 Animal 4
0.261
0.321
0.039
0.005
Cage 2 Animal 4
0.061
0.058
0.053
0.009

Table 15
Morphine + MP-III-024 (Ratio → 1.0:0.31) Response Rate Values

Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg
Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg

Cage 1 Animal 1
0.337
0.286
0.059
0.000
Cage 2 Animal 1
0.016
0.016
0.010
0.000

Cage 3 Animal 4
0.044
0.035
0.009
0.000
Cage 2 Animal 2
0.034
0.035
0.038
0.000
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Cage 3 Animal 2
0.158
0.038
0.049
0.000
Cage 3 Animal 3
0.034
0.057
0.024
0.000

Table 16
Morphine + MP-III-024 (Ratio → 1.0:0.94) Response Rate Values

Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg
Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg

Cage 1 Animal 1
0.266
0.528
0.231
0.034
Cage 2 Animal 1
0.002
0.046
0.013
0.000

Cage 1 Animal 2
0.057
0.061
0.096
0.021
Cage 2 Animal 2
0.038
0.003
0.074
0.000

Cage 2 Animal 3
0.103
0.073
0.017
0.115

Cage 1 Animal 4
0.018
0.015
0.216
0.016
Cage 2 Animal 4
0.202
0.170
0.081
0.003

Table 17
Morphine + MP-III-024 (Ratio → 1.0:2.8) Response Rate Values

Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg
Vehicle
3.2 mg/kg
10 mg/kg
32 mg/kg

Cage 2 Animal 1
0.033
0.016
0.017
0.000

Cage 3 Animal 4
0.087
0.052
0.041
0.006
Cage 2 Animal 2
0.071
0.080
0.061
0.000

Cage 3 Animal 2
0.251
0.084
0.043
0.000
Cage 3 Animal 3
0.062
0.027
0.031
0.023

Note. Tables 14-17: Self-administration response rate values for morphine alone and
morphine in combination with MP-III-024 at varying ratios. The data collected for the
vehicle, which acted as our control, was compared to the animals’ response rate values at
3.2, 10, and 32 mg/kg doses of morphine or morphine + MP-III-024 in order to observe the
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behavioral disruptions induced by morphine and/or the drug mix. The greyed areas on the
tables represent deceased animals or animals removed from the study.

2.4.4. Food Self-Administration Response Rates Graph

Figure 9
Morphine and MP-III-024 Self-Administration Response Rates Graph

Note. The graph above depicts the food self-administration response rate values for
morphine and morphine + MP-III-024, our combination drug therapy. We wanted to know
if MP-III-024 would enhance or reduce morphine’s behavioral effects at varying ratios.
The x-axis represents the injected dose of morphine alone or morphine + MP-III-024 (3.2,
10, or 32 mg/kg), as well as our vehicle control, while the y-axis represents the animals’
response rates. Two-way ANOVA revealed that morphine significantly reduced the
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animals’ operant responding, but the drug mix at every tested ratio (1.0:0.31, 1.0:0.94, and
1.0:2.8) did not significantly reduce response rates in comparison to morphine alone.
Therefore, it can be concluded that morphine co-administered with MP-III-024 has
statistically indistinguishable effects from morphine alone but adding MP-III-024 to
morphine does not make morphine more disruptive. If anything, there is a slight rightward
shift at the 1.0:0.94 ratio, which is indicative of a possible subadditive (anti-synergistic)
effect. All results are presented as means ± SEM.

From the data collected from the MED-PC program, as well as the two-way
analysis of variance (ANOVA), it was concluded that morphine induced disruption in food
self-administration for the mice, especially the higher the dose. Comparingly, when
morphine was given in combination with MP-III-024, we found the effects to be
statistically indistinguishable from morphine alone. However, adding MP-III-024 to
morphine did not make morphine more disruptive. In fact, we found that the disruption in
food-self administration caused by morphine was somewhat restored when coadministered with MP-III-024, as indicated by the upper, rightward shift on the doseresponse curves, most notably at the 1.0:0.94 morphine:MP-III-024 ratio. This behavioral
restoration was most evident when analyzing morphine + MP-III-024’s response rates in
comparison to morphine’s response rates. Two-way ANOVA demonstrated that the drug
mix at every tested ratio (1.0:0.31, 1.0:0.94, and 1.0:2.8) did not significantly reduce the
mice’s motivation to nose poke for palatable food rewards. Decreases or increases in
animals’ response rates (in our study, how fast or slow the mice nose poked) are more
indicative of true behavioral changes in comparison to other outputs, like earned rewards.
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Seemingly, at an almost 1:1 ratio, morphine co-administered with MP-III-024 does not
induce behavioral disruptions in food self-administration, which is suggestive of a
subadditive (anti-synergistic) effect.

2.4.5. Fischer et al.’s Findings

Figure 10
Fischer et al.’s MP-III-024 Food Self-Administration Graphs
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Note. Each graph represents the effects of different doses (3.2, 10, 32, and 100 mg/kg) of
MP-III-024 on operant behavior. The x-axis depicts the time-course in minutes of each
individual dose following i.p. injections. The behavior of the mice was accessed at 10, 20,
40, 80, and 160 minutes post-injection. Likewise, the y-axis depicts the percent control of
the animals’ response rate post-injection in comparison to their baseline rate, that being
0.91 ± 0.03 responses per second. Each data point is the average of 8-10 mice. This set of
self-administration testing was conducted by Fischer et al. at Cooper Medical School of
Rowan University (CMSRU) in 2017.[45]

According to Fischer et al.’s research paper titled Pharmacological and
antihyperalgesic properties of the novel α2/3 preferring GABAA receptor ligand MP-III024, MP-III-024 did not decrease the animals’ operant response rates across any dose.[45]
Therefore, an ED50 value could not be determined.[45] This is a good indication that when
given in combination with morphine, a drug that is known to negatively affect operant
behavior, MP-III-024 may help to neutralize morphine’s side effects and fully or somewhat
restore response rates to their baseline state.
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2.4.6. Open Field Data and Results

Figure 11
Morphine and MP-III-024 Open Field Graph

Note. Graph for open field testing which depicts the locomotor activity of the mice using a
cumulative dosing procedure (n = 8 per group). The x-axis represents the cumulative drug
dose each animal received every 30 minutes, while the y-axis represents the distance the
mice traveled in meters while in the open field chambers during each test session. Injections
consisted of morphine or MP-III-024 alone or different drug mix ratios of morphine + MPIII-024. Morphine alone induced a clear hyperlocomotive effect, while MP-III-024 alone
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did not. At the 1.0:0.94 ratio of morphine in combination with MP-III-024, a rightward
shift in the activation of locomotor activity was demonstrated, a subadditive (antisynergistic) effect. Contrastingly, two-way ANOVA revealed there was not a significant
difference between morphine alone and the 1.0:0.31 and 1.0:2.8 drug mix ratios, despite
what looks to be an increase in locomotion at both those ratios. All results are presented as
means ± SEM.

Figure 12
Morphine and MP-III-024 Open Field Graph Showing Significance

Note. Additional graph depicting the open field locomotor activity of the mice (n = 8 per
group). The x-axis represents the cumulative drug dose each animal received every 30
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minutes, while the y-axis represents the distance the mice traveled in meters while in the
open field chambers during each test session. Two-way ANOVA determined a significant
difference between morphine alone and the 1.0:0.94 ratio, as indicated by the asterisks (**
means p < 0.01). In other words, the 1.0:0.94 ratio was statistically less than morphine
alone, meaning it had a subadditive (anti-synergistic) effect. Two-way ANOVA also
determined that there was not a significant difference between morphine alone and the
1.0:0.31 and 1.0:2.8 ratios, even though it looks like there could have been a synergistic
effect at those two ratios when just analyzing the graph itself. All results are presented as
means ± SEM.

When morphine alone was administered to the mice during open field testing,
locomotor function was increased dose-dependently. In other words, morphine produced
dose-dependent increases in locomotor activity. Contrastingly, when MP-III-024 alone was
administered to the mice, no effect was observed, something that Fischer et al. also noticed
back in 2017. Therefore, the effects of morphine and MP-III-024 were said to be
heteroergic, with morphine having an effect and MP-III-024 lacking an effect. When given
in combination, we expected to continue to see dose-dependent increases in locomotor
activity, meaning more movement from the mice the higher the dosage of morphine + MPIII-024. At first, we thought this was true for two out of our three drug mix ratios, 1.0:0.31
and 1.0:2.8; but, after two-way ANOVA, it was revealed that there was not a significant
difference between morphine alone and the 1.0:0.31 and 1.0:2.8 ratios. However, for the
1.0:0.94 ratio, two-way ANOVA determined there was a significant difference between
morphine alone and that particular ratio. More specifically, the 1.0:0.94 ratio was
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statistically less than morphine alone, as demonstrated by the rightward shift for that
proportion on the open field locomotor activity graphs (Figures 11 and 12). Along with our
inferences from the statistical analysis, this rightward shift in the activation of locomotor
activity is indicative of a subadditive (anti-synergistic) effect. Together, with our previous
findings, it can be concluded that by adding a α2/α3GABAA PAM to a MOR agonist, the
analgesic-like effects of the MOR agonist can be potentiated without simultaneously
increasing (and possibly even decreasing) effects unrelated to analgesia, like locomotor
function, as witnessed through our open field testing.

2.5. Discussion
In conjunction with the data and results collected throughout the duration of this
study and the insight provided by Fischer et al.’s publication regarding MP-III-024, it was
concluded that the drug mix, morphine + MP-III-024, at all three tested ratios (1.0:0.31,
1.0:0.94, and 1.0:2.8) was statistically indistinguishable from morphine alone; however,
adding MP-III-024 to morphine did not make morphine more disruptive during food selfadministration. This means that unlike Rahman et al.’s findings, morphine + MP-III-024
are not always synergistic when administered in combination. If anything, there was a
slight rightward shift at the 1.0:0.94 ratio, most obvious when looking at the food selfadministration response rate graph (Figure 9). This is indicative of a possible subadditive
(anti-synergistic) effect. Subadditivity regarding drug combinations “occurs when one drug
interferes with the action of the other to decrease its effect.”[2] The effect of morphine in
combination with MP-III-024 at an almost 1:1 ratio would be subadditive rather than
antagonistic because each individual drug is working on a different site of action, morphine
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being µ-opioid receptors (MORs) and MP-III-024 being α2/α3GABAA receptors. When
looking at each drug alone, morphine negatively impacted food self-administration,
something that we expected to happen based on opioids’ known side effects. Contrastingly,
MP-III-024, when administered by itself, did not disrupt rodent operant response rates
across any dose when compared to the vehicle control, thus leading Fischer et al. to
conclude that MP-III-024 was ineffective at inducing behavioral toxicity.[45] With the
results of this study, we now know that morphine + MP-III-024 is not universally
synergistic; therefore, this combination drug therapy may be able to fully promote
analgesia without posing a lot of harmful health risks.
Furthermore, in regard to open field testing, we found that morphine + MP-III-024
also has a subadditive (anti-synergistic) effect when it comes to locomotor function at a
1.0:0.94 morphine to MP-III-024 ratio. This conclusion was based on our statistical
analysis (i.e., two-way ANOVA), as well as the rightward shift that was produced when
morphine was co-administered with MP-III-024 at this ratio. Solely, morphine is known to
increase locomotion in rodent models, especially at higher doses. However, MP-III-024
alone was found to be ineffective.
So far, we now know that morphine + MP-III-024 has a synergistic effect regarding
analgesia and a subadditive (anti-synergistic) effect regarding behavioral disruption and
locomotion at approximately a 1:1 ratio. These findings suggest that unlike morphine,
which dampens pain signals and responses in the central and peripheral nervous system,
MP-III-024 may only dampen pain signals, not necessarily pain responses. In other words,
MP-III-024 may only impact the PNS, not the CNS, therefore causing a combination
therapy of morphine and this imidazodiazepine PAM to be void of a synergistic side effect
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profile, especially if MP-III-024 is not interacting with the CNS, which controls most
functions of the body and mind[91]. Additionally, one of the reasons we might not have seen
a synergistic side effect profile in this drug combination is because MP-III-024 is
α2/3GABAA selective; Fischer et al.’s study showed that there are little to no side effects
associated with the α2/3GABAA receptors.[45] Rather, the negative side effects associated
with benzodiazepines, such as sedation and respiratory depression, as discussed previously,
are linked to the α1GABAA receptors.[45] Thus, a dual MOR-α2/α3GABAA-acting
pharmacotherapy that treats pain with minimal to no side effects is achievable.
Nevertheless, in order to determine the full therapeutic window of this dual
pharmacology approach, additional testing will need to be carried out; tolerance will be
measured by repeated hot plate testing, constipation will be assessed by a charcoal transit
assay, respiratory depression will be evaluated by plethysmography, and abuse liability
will be analyzed using conditioned place preference (CPP) tests, which are currently
underway. If successful, these studies will identify a new method to enhance opioid
analgesia without requiring high doses of opioid medications to be taken, in turn reducing
the likelihood of patients developing opioid dependence and addiction.
It is important to acknowledge that there were some limitations in regard to this
experiment. The most notable limitation is the fact that this study only evaluated male mice,
not female mice. This is something to consider, especially since there are noteworthy sexrelated differences in male and female mice, which can influence behavior and responses
to drugs of abuse.[52] For example, there are sex-mediated differences in opioid receptor
expression and signaling.[46] This could potentially have an impact on the drug mix results.
Perhaps, the data would be variable if only female mice or a mixture of male and female
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mice were utilized. Moreover, it is important to address the fact that prolonged and/or
repeated intraperitoneal administration can cause a degree of stress and discomfort in mice
(this is especially true for cumulative dosing); injection retraining techniques may also add
a level of stress.[92] When the drug mix injections were initiated, the animals had already
been poked a handful of times from the morphine and/or MP-III-024 injections and
additional injections may have become a stressor to the animals, thus causing some of the
mice to underperform. Additionally, a few of our mice used for self-administration were
found to have pre-existing health issues, which we discovered after initiating testing. This
could also have impacted some of the animals’ operant responding.
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CHAPTER 2: KEY TAKEAWAYS

Self-Administration Conclusions:
❖ Morphine induced behavioral disruptions in the mice, especially when administered
at high doses, thus negatively impacting food self-administration
❖ MP-III-024 did not disrupt the animals’ operant response rates across any dose when
compared to the vehicle control, thus producing negligible effects regarding food
self-administration
❖ MP-III-024 did not alter morphine-induced behavioral disruption; in fact, MP-III024 may have produced a subadditive (anti-synergistic) effect at the 1.0:0.94
morphine:MP-III-024 ratio

Open Field Conclusions:
❖ Morphine increased locomotor activity, whereas MP-III-024 had no effect on
locomotor function
❖ The 1.0:0.31 and 1.0:2.8 morphine:MP-III-024 ratios produced a non-significant
enhancement of morphine-induced hyperlocomotion
❖ The 1.0:0.94 morphine:MP-III-024 ratio demonstrated a statistically significant
subadditive (anti-synergistic) effect

Overall Conclusions:
− Morphine + MP-III-024 enhances analgesia-like effects
− MP-III-024 does not enhance morphine induced disruptions
− Therefore, MP-III-024 is NOT universally synergistic with morphine

NOTE: Interactive effects of drug mixes depend on their relative proportions; there are
key differences in the 1.0:0.31, 1.0:0.94, and 1.0:2.8 morphine:MP-III-024 ratios’ effects
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Chapter 3
The Effects of the Dopamine D4 Receptor Antagonist CAB-01-019 on Alcohol and
Palatable Food Self-Administration

3.1. Abstract
Alcohol use disorder (AUD) is characterized as an uncontrollable drinking problem
as a result of physical and/or emotional dependence on alcohol. According to the National
Survey on Drug Use and Health (NSDUH), nearly 15 million people ages 12 and over
suffer from AUD in the United States. This chronic disease continues to be a major health
issue with little relief from current pharmacotherapeutic treatments. Therefore, AUD
requires the identification of new targets for developing alternative treatment options. In
this study, the dopamine D4 receptor (D4R) full antagonist, CAB-01-019, was explored as
a potential therapy for AUD. This experimental compound was tested on eight CD-1 mice
to see how its effects impact food self-administration. Over a two-month period, the mice
were trained to nose poke for palatable food rewards in the form of vanilla Ensure and
water. After the animals were fully trained, they were injected with either a vehicle control
or CAB-01-019 in order to observe the drug’s effect on the mice’s behavioral responses in
comparison to the control. Through one-way ANOVA, it was demonstrated that CAB-01019 did not significantly reduce operant responding at any of the three tested doses (10,
17.8, and 30 mg/kg) when looking at reward and response rate values. Since CAB-01-019
did not evoke any type of behavioral disruption, we can continue on with our testing and
see its effect on rodent models of alcohol addiction. We propose CAB-01-019 will reduce
alcohol-taking and -seeking behaviors during ethanol self-administration.
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3.2. Introduction
Just like opioid use disorder (OUD) is a major health problem around the globe, so
is alcohol use disorder (AUD), sometimes known as alcoholism. AUD is medically
characterized as a brain disorder that impairs an individual’s ability to discontinue or
control alcohol consumption regardless of adverse social, occupational, and/or health
consequences.[57] Lasting changes in the brain as a result of alcohol misuse often perpetuate
AUD and make those who readily abuse alcohol more susceptible to relapse.[57] According
to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), a person’s risk of
developing AUD is directly correlated to how much, how often, and how quickly one
consumes alcohol.[57] Nevertheless, there are other factors that increase the risk of AUD,
such as drinking from an early age, genetics and family history of alcohol issues, mental
health conditions (e.g., depression, PTSD, and ADHD), and a history of trauma, especially
trauma stemming from childhood.[57]
The 2019 National Survey on Drug Use and Health (NSDUH) estimated that
414,000 adolescents between the ages of 12 to 17, 1.7% of this age group, suffer from
AUD.[93] Underage drinking not only interferes with normal adolescent brain development,
but contributes to a variety of acute consequences, including injuries (e.g., falls, burns, and
drownings), sexual assaults, alcohol overdoses, and deaths, especially from motor vehicle
crashes, suicides, and homicides.[93] In comparison, the NSDUH estimated that 14.5
million people ages 12 and older, 5.3% of this age group, suffer from AUD.[93] This number
incorporates 9.0 million men and 5.5 million women.[93] Each year, approximately 95,000
people succumb to alcohol-related causes, thus making alcohol the third-leading
preventable cause of death in the United States behind tobacco use and poor diet and
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physical inactivity, respectively.[93] For example, in 2019, alcohol impaired driving
fatalities were responsible for 10,142 deaths, accounting for 28.0% of the overall driving
fatalities for that year.[93] The World Health Organization (WHO) considers the harmful
use of alcohol to be a causal factor in the development of more than 200 diseases and injury
related health conditions, which may lead to premature death and disability.[93]
Alcohol has short- and long-term effects on the body. After substantial oral
absorption has taken place following consumption of an alcoholic beverage, alcohol enters
the bloodstream.[94] The more a person drinks, the higher the blood alcohol concentration
(BAC) climbs.[94] As an individual’s BAC elevates, a greater degree of intoxication and
impairment occur.[94] These effects include but are not limited to slurred speech, motor
impairment, confusion, and memory and concentration problems.[94] Alcohol’s immediate
effects appear within 10 minutes of consumption.[94] Excessive alcohol use, whether on a
single occasion (binge drinking) or over time (chronic drinking), can negatively impact
one’s health and lead to long-term health problems, most notably associated with the brain,
heart, liver, pancreas, and immune system.[95] Heavy drinking, especially, takes a serious
toll on the liver and can lead to a variety of complications, like steatosis (or fatty liver),
alcoholic hepatitis, fibrosis, and cirrhosis.[95] Likewise, drinking alcohol increases the risk
of a person developing several kinds of cancers, such as head and neck (i.e., mouth,
pharynx, and larynx), esophagus, liver, breast, and colorectal.[96]
Although alcohol affects many different aspects of the body, the area we are most
concerned about in this study is the brain, specifically its dopamine receptors. It is no secret
that alcohol has a profound effect on the complex structures of the brain.[97] Alcohol blocks
chemical signals between brain cells (i.e., neurons), thus resulting in immediate symptoms
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of intoxication, as discussed previously.[97] If excessive drinking persists over an extended
period of time, the brain begins to adapt to these blocked signals by over activating specific
brain chemicals (i.e., neurotransmitters).[97] This, in turn, may result in neurotoxicity;
neurotoxicity occurs when neurons overreact to neurotransmitters for too long, eventually
causing certain neurons to “burn out.”[97] Along with pathway damage, heavy drinking has
the potential to harm brain matter itself.[97] Individuals with alcohol dependence oftentimes
experience brain shrinkage, a reduction in the volume of gray and white matter that
compose the brain.[97] Gray matter consists primarily of cell bodies, whereas white matter
is associated with the cell pathways of the central nervous system (CNS).[97]
Formerly, scientists believed that alcohol acted as a membrane disruptor that
inflicted a generalized effect all over the brain, especially since its small molecules have
the ability to freely diffuse and penetrate the blood-brain barrier (BBB).[64] However,
scientists now know that this notion is not entirely true; rather, there are particular
structures in the brain that alcohol targets, the most notable being γ-aminobutyric acid
(GABA) receptors, glutamate receptors, and the nucleus accumbens.[64] GABA is known
to be the major inhibitory neurotransmitter in the brain.[64] Alcohol is thought to imitate
GABA’s inhibitory effect by binding to GABA receptors and hindering neuronal
signaling.[64] Likewise, alcohol has been found to inhibit glutamate, the major excitatory
neurotransmitter in the brain, especially at the N-methyl-D-aspartate (NMDA) glutamate
receptor.[64] Both GABA and glutamate are often associated with the sedative effects of
alcohol.[98] The nucleus accumbens, on the other hand, plays a major role in the brain’s
reward pathway.[99] This important middle brain structure helps to maintain motivation,
pleasure, satiety, and memories.[99] When consumed, alcohol tends to activate the brain’s
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whole reward system.[64] Consumption, even in small doses, enhances the amount of
dopamine, the neurotransmitter that mediates pleasure in the brain, released by the nucleus
accumbens.[64] Since the nucleus accumbens is part of the neuronal circuit that regulates
reward-seeking behavior and alcohol produces feelings of euphoria and well-being by
intensifying the release of dopamine throughout the body, the brain is easily tricked into
thinking that alcohol is a system of positive reinforcement; this is one of the main reasons
why alcohol is so addictive and provokes relapse.[64] Along with dopamine, alcohol also
affects serotonin and acetylcholine activity.[98]
Due to alcohol’s profound effect on the brain’s dopaminergic receptors, it is
plausible to hypothesize that medications that target dopamine receptors may be up-andcoming treatment options for people suffering from AUD. Previous studies have shown
that antagonism of the dopamine D4 receptor (D4R) reduces drug-taking and -seeking
behaviors in rodent models of cocaine addiction, therefore representing a new, explorable
area of medication development for various substance use disorders.[66] Our drug of interest
for this study, CAB-01-019, is a full antagonist of D4R.[66] D4Rs are G protein-coupled
receptors (GPCRs) and are a member of the D2-like subfamily of dopamine receptors.[66]
In comparison to the other D2-like receptors (i.e., D2R and D3R), D4Rs exhibit the lowest
level of expression in the brain but have a distinct distribution.[66] D4Rs are mainly
expressed in the prefrontal cortex and hippocampus, where they are involved with neuronal
functions that affect attention and exploratory behavior, as well as performance in object
recognition and inhibitory avoidance cognitive tasks.[66] Originally, budding medications
aimed at targeting D4Rs were thought to be good candidates for combating certain
antipsychotic conditions, such as schizophrenia.[66] While D4R proved to be an
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unsuccessful target for schizophrenia treatment, recent studies utilizing the full antagonist,
CAB-01-019, have shown D4Rs to have potentiality when it comes to being a
pharmacological target for the treatment of addiction.[66] Preliminary data using this drug
demonstrated that it attenuated cocaine self-administration in rats (personally
communicated to Dr. Keck by Takato Hiranita and Scott Hemby); cocaine is a highly
addictive stimulant drug that, similar to alcohol, has a profound effect on the dopaminergic
receptors of the brain.[66] In conjunction with these findings and the commonalities between
cocaine and alcohol’s effect on dopamine, we propose that CAB-01-019 will also attenuate
drug-taking and -seeking behaviors in animal models of AUD and prove to be a promising
new avenue for AUD medication development.
To date, there are three FDA-approved medications on the market for the treatment
of AUD: disulfiram, naltrexone, and acamprosate.[59] Disulfiram was the first to be
approved by the FDA in 1951.[63] This drug works by inhibiting the metabolism of alcohol,
thus causing acetaldehyde, a highly toxic substance, to build up in the body.[63] As a result
of this, when a person drinks even the smallest amount of alcohol, unpleasant symptoms
(e.g., nausea, heart palpitations, and flushing) rapidly arise.[59,63] Therefore, disulfiram is
said to be a psychological deterrent to alcohol use.[63] Naltrexone, on the other hand, was
approved by the FDA in 1994 as an oral medication and then again in 2006 as an extendedrelease injectable.[63] Unlike disulfiram, this drug is a pure opioid receptor antagonist,
meaning it blocks the pleasurable effects of alcohol by inhibiting the µ-opioid
receptor.[59,63] Alcohol consumption is known to stimulate endogenous opioid release and
enhance dopamine transmission throughout the body.[59] If naltrexone makes alcohol
ingestion less rewarding by interfering with its euphoric effect, then it is expected that
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heavy drinking habits will eventually decrease.[63] Likewise, the last drug to be approved
by the FDA in 2004 as a potential treatment option for people suffering from AUD was
acamprosate.[63] Although its mechanism of action remains uncertain, this drug is believed
to help restore the homeostasis between neuronal excitation (glutamatergic) and inhibition
(GABAergic) that heavy drinking, as well as withdrawal, are known to dysregulate through
interactions with NMDA receptors.[59,63] Research has shown acamprosate to be most
effective at maintaining abstinence in patients experiencing alcohol dependence.[59] Even
though there are several treatment options out there when it comes to treating AUD, as just
discussed, there is still room for new pharmacotherapies to be explored that offer more
precise receptor selectivity, less adverse effects, and strong compliance rates. We
hypothesize that CAB-01-019, due to its D4R antagonism, will attenuate alcohol-taking
and -seeking behaviors and thus could be a new AUD therapeutic.
In order to determine whether CAB-01-019 affects alcohol-taking and -seeking
behaviors, we proposed to determine its effects on alcohol self-administration in mice.
Herein, we report the effects of CAB-01-019 on palatable food self-administration in mice,
a test that serves as 1) a control for alcohol tests, separating alcohol-specific effects from
non-specific behavioral and appetitive effects, and 2) as a training precursor for ethanol
self-administration; animals are trained to self-administer ethanol only after learning to
self-administer food. The future directions of this experiment seek to determine CAB-01019’s effects on operant alcohol self-administration in rodent models of AUD.
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3.3. Materials and Methods

3.3.1. Drug
3.3.1.1. CAB-01-019. Our drug of interest for this study was CAB-01-019, a full
antagonist of the dopamine D4 receptor (D4R), as measured by Gαi/o-mediated signaling
and β-arrestin2 recruitment (manuscript in preparation).[66] CAB-01-019 was synthesized
by our collaborators at High Point University. This drug has been found to dosedependently attenuate intravenous cocaine self-administration in rats (personally
communicated to Dr. Keck by Takato Hiranita and Scott Hemby).[66] Importantly, studies
by our collaborators have determined that 17.8 mg/kg of CAB-01-019 significantly reduces
cocaine intake; non-specific effects (e.g., reduced food self-administration, reduced
internal body temperature) are evident only at 32 mg/kg or higher.[66] Additionally, CAB01-019 has facile membrane permeation.[66] During central nervous system multiparameter
optimization (CNS MPO) testing, which helps evaluate whether certain drugs will be able
to cross the blood-brain barrier (BBB), CAB-01-019 scored a 4.5; scores ≥4 have
demonstrated a correlation to CNS penetrance.[66,100] When compared to the known brainpenetrant CNS ligand, buspirone, CAB-01-019’s permeability (27 × 10-6 cm/s) surpassed
buspirone’s previously established permeability value (25 × 10-6 cm/s), thus suggesting
that CAB-01-019 should be able to easily penetrate the BBB and produce a therapeutic
effect.[66]
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Figure 13
Chemical Structure of CAB-01-019

[66]

3.3.2. Drug Dosing
CAB-01-019 was administered at three doses, 10, 17.8, and 30 mg/kg, during this
experiment, using a Latin square design. A vehicle composed of 5% Tween 80 and 5%
propylene glycol in 0.9% NaCl (saline) was also used as our control. Both CAB-01-019
and the vehicle were administered to the mice via intraperitoneal (i.p.) injections. The
amount of injected solution was based on each animal’s body weight; weights were
determined on the morning of designated injection days.

3.3.3. Animals
The animals used for testing were drug-naïve adult male CD-1 mice obtained from
Charles River Laboratories. Similar to our morphine and MP-III-024 addiction and pain
study, the animals were not exposed to any kind of behavioral or pharmacological
manipulation prior to this experiment. Each mouse weighed between 30-45 grams; weights
often fluctuated due to daily fasting. The animals were cared for in accordance with the
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guidelines of the Institutional Animal Care and Use Committee of Rowan University and
all testing followed the “Guide for the Care and Use of Laboratory Animals.”

3.3.4. Equipment
3.3.4.1. Operant Chambers. The apparatuses used for this behavioral study were
operant chambers. As previously mentioned in the subsequent chapter on morphine and
MP-III-024, each operant chamber was equipped with a reward receptacle located between
two nose poking response holes. The left nose poke hole was designated the correct hole
and when poked, the animals received a food reward, that being a 50/50 combination of
vanilla Ensure and water. Contrastingly, the right nose poke hole was designated the
incorrect hole and when poked, did not render a food reward for the animal. Over a period
of about two months, the mice were trained to nose poke using a fixed ratio (FR) system.
The animals were started at an FR 1 and gradually increased to an FR 4.
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Figure 14
Animals and Testing Apparatus for CAB-01-019 Self-Administration

Note. Picture of a CD-1 mouse in an operant chamber. This type of animal and testing
apparatus was used for our CAB-01-019 food self-administration experiment.

3.3.5. Experimental Procedure
3.3.5.1. Food Self-Administration Procedure. Eight CD-1 mice were trained to
nose poke for rewards for approximately two months. Each testing session was 120
minutes, or two hours, and was carried out seven days a week. Once the mice reached a
consistent reward response at an FR 4, the animals were injected on designated injection
days with CAB-01-019 and placed in the operant chambers. Once in the chambers, the
MED-PC program analyzed the animals’ disruption in food self-administration caused by
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the drug. This analysis included important information, such as number of rewards received
and response rates. A “rest” day was placed in between each injection day, which consisted
of regular self-administration testing (i.e., training). The animals were allowed to eat for
one hour after daily testing sessions, then fasted overnight for ~21 hours for the following,
next day experiment.

3.4. Data and Results

3.4.1. Food Self-Administration Reward Values

Table 18
CAB-01-019 Reward Values

Vehicle
10 mg/kg
17.8 mg/kg
30 mg/kg
Vehicle
10 mg/kg
17.8 mg/kg
30 mg/kg

Cage 1 Animal 1
100
100
100
81
Cage 2 Animal 1
100
100
100
98

Cage 1 Animal 2
100
77
98
92
Cage 2 Animal 2
100
100
100
72

Cage 1 Animal 3
100
100
95
100
Cage 2 Animal 3
83
80
23
50

Cage 1 Animal 4
78
44
75
56
Cage 2 Animal 4
100
100
100
100

Note. The chart above displays the food self-administration reward values for the full D4R
antagonist, CAB-01-019, at 10, 17.8, and 30 mg/kg (n = 8). The rewards earned at these
three doses were compared to each animal’s vehicle reward value. A vehicle composed of
5% Tween 80 and 5% propylene glycol in 0.9% NaCl (saline) was used as our control. Our
goal was to see if CAB-01-019 induces behavioral disruptions.
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3.4.2. Food Self-Administration Rewards Graph

Figure 15
CAB-01-019 Food Self-Administration Rewards Graph

Note. The graph above depicts the food self-administration reward values of CAB-01-019
(n = 8). The x-axis represents the injected dose of CAB-01-019 (10, 17.8, or 30 mg/kg), as
well as our vehicle control, while the y-axis is the number of earned rewards. One-way
ANOVA revealed that CAB-01-019 did not significantly reduce palatable food selfadministration at any of the three doses. All results are presented as means ± SEM.
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3.4.3. Food Self-Administration Response Rate Values

Table 19
CAB-01-019 Response Rate Values

Vehicle
10 mg/kg
17.8 mg/kg
30 mg/kg
Vehicle
10 mg/kg
17.8 mg/kg
30 mg/kg

Cage 1 Animal 1
0.187
0.096
0.069
0.045
Cage 2 Animal 1
0.921
0.189
0.106
0.054

Cage 1 Animal 2
0.110
0.044
0.055
0.052
Cage 2 Animal 2
0.060
0.070
0.059
0.040

Cage 1 Animal 3
0.059
0.087
0.053
0.082
Cage 2 Animal 3
0.047
0.044
0.013
0.028

Cage 1 Animal 4
0.044
0.025
0.042
0.031
Cage 2 Animal 4
0.176
0.157
0.061
0.066

Note. The chart above displays the food self-administration response rate values for CAB01-019, at 10, 17.8, and 30 mg/kg (n = 8). The response rates at these three doses were
compared to each animal’s vehicle response rate, which acted as our control.
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3.4.4. Food Self-Administration Response Rates Graph

Figure 16
CAB-01-019 Food Self-Administration Response Rates Graph

Note. The graph above depicts the food self-administration response rate values of CAB01-019 (n = 8). The x-axis represents the injected dose of CAB-01-019 (10, 17.8, or 30
mg/kg), as well as our vehicle control, while the y-axis represents the animals’ response
rates. One-way ANOVA revealed that CAB-01-019 did not significantly reduce operant
responding at any of the three doses. Therefore, it can be concluded that CAB-01-019 does
not induce behavioral disruptions in mice trained to self-administer food. All results are
presented as means ± SEM.
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From the rewards and response rates data collected from the MED-PC program, as
well as the one-way ANOVA, it was revealed that CAB-01-019 did not significantly
attenuate food self-administration at any of the three tested doses (10, 17.8, or 30 mg/kg).
This means that this dopamine D4 receptor (D4R) full antagonist may be able to reduce
drug-taking and -seeking behaviors with few disruptive side effects.

3.4.5. Food Self-Administration Response Rates Graphs Taking into Consideration the
Outlier Vehicle Animal

Figure 17
Response Rates Graph Focusing on the Outlier Vehicle Animal
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Note. Food self-administration response rate graph for CAB-01-019 depicting the outlier
animal in the vehicle group, which contributed to the long error bars in the preceding
response rate graph (Figure 16). When it comes to response rates during selfadministration, a normal response rate is considered to be around 0.1. However, this
particular outlier had a response rate of 0.921. A number of factors could contribute to this
above average value, such as the animal being really well-trained or extremely hungry on
that specific test day.

Figure 18
Response Rates Graph Without the Inclusion of the Outlier Vehicle Animal
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Note. The graph above depicts the food self-administration response rate values of CAB01-019 without the outlier (n = 7 for vehicle group). The x-axis represents the injected dose
of CAB-01-019 (10, 17.8, or 30 mg/kg), as well as our vehicle control, while the y-axis
represents the animals’ response rates. What is notable in this graph is the length of the
error bars for the vehicle dose in comparison to the preceding food self-administration
response rate graph (Figure 16) with the outlier still averaged in. Without the outlier
animal, the margin of error for the vehicle is much smaller. All results are presented as
means ± SEM.

3.5. Discussion
When it comes to alcohol use disorder (AUD), treatment options are scarce and the
few available are often underused. According to the 2019 National Survey on Drug Use
and Health (NSDUH), an estimated 7.2% of the people suffering from AUD received any
treatment in the past year.[93] Likewise, less than 4% of individuals diagnosed with AUD
were prescribed one of the three medications approved by the U.S. Food and Drug
Administration (FDA) to treat their disorder.[93] This is concerning. Although disulfiram,
naltrexone, and acamprosate are on the market to help people stop or reduce their drinking
habits and prevent relapse, medication compliance tends to be poor, especially as a result
of their side effects or intense daily dosing regimens (often requiring supervision).[59,63] In
fact, disulfiram is no longer considered a first-line treatment option for AUD because of
difficulties with adherence, as well as its toxicity.[62] The American Psychiatric Association
(APA) recommends that disulfiram only be given to patients who are intolerant to or have
not responded well to naltrexone or acamprosate.[62] Due to the low success rates
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surrounding these treatments for AUD, there is a clear need for new therapeutics to be
explored, one being the dopamine D4 receptor (D4R) full antagonist, CAB-01-019.
Thus far, our food self-administration study with CAB-01-019 has been successful
and we are hopeful that this success will continue on into our ethanol self-administration
study (which is currently underway), with this drug proving to be a new potential treatment
option for AUD. Our results demonstrated that CAB-01-019 did not attenuate food selfadministration at any of the three tested doses (10, 17.8, and 30 mg/kg). This is a significant
finding because we are looking for a drug that not only has strong receptor selectivity but
causes minimal disruptive side effects. In our sample set of mice not yet addicted to
alcohol, we were able to see that CAB-01-019 does not seem to interrupt the animals’
desire and motivation to eat. We can now use these results as a critical control for our
ongoing alcohol tests, helping us to separate alcohol-specific effects from non-specific
behavioral or appetitive effects.
Furthermore, if CAB-01-019 proves to be successful in rodent models of alcohol
addiction, this will be the first drug to offer precise receptor selectivity, targeting the
dopaminergic receptors in the brain, which alcohol is known to profoundly affect. When it
comes to disulfiram, naltrexone, and acamprosate, their mechanisms of action in regard to
alcohol are still not fully understood. This is problematic and shows that there is no proof
that these three drugs effectively treat AUD. A drug needs to be discovered that completely
and efficiently targets areas in the brain associated with AUD, like the dopamine receptors
in the nucleus accumbens, a major component of the brain’s reward system. This in turn
will affect alcohol-taking and -seeking behaviors and hopefully reduce alcohol
consumption in those suffering from alcoholism.
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Just like our study with morphine and MP-III-024, it is important to acknowledge
that there were some limitations in regard to our CAB-01-019 experiment. The most
notable limitation is the fact that this study only evaluated male mice, not female mice.
This is something to consider, especially since there are noteworthy sex-related differences
in behavioral and physiological responses to drugs in rodents, including efficacy and
potency.[3] Therefore, it is often necessary to test both sexes. Perhaps, the data would be
variable if only female mice or a mixture of male and female mice were utilized.
Additionally, there is a possibility that food restriction may have an effect on D4R receptor
expression and/or signaling; however, there is currently no published data regarding this.
It would be interesting to see how CAB-01-019 affects the operant responding of mice who
are not food restricted and compare the results to our food self-administration mice who
are fasted on a daily basis.
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